POPULARITY
Categories
920 episodes with Oral
850 episodes with Oral
848 episodes with Oral
946 episodes with Oral
133 episodes with Oral
127 episodes with Oral
256 episodes with Oral
439 episodes with Oral
87 episodes with Oral
76 episodes with Oral
168 episodes with Oral
77 episodes with Oral
51 episodes with Oral
84 episodes with Oral
162 episodes with Oral
64 episodes with Oral
42 episodes with Oral
59 episodes with Oral
891 episodes with Oral
44 episodes with Oral
46 episodes with Oral
45 episodes with Oral
87 episodes with Oral
28 episodes with Oral
31 episodes with Oral
38 episodes with Oral
21 episodes with Oral
84 episodes with Oral
31 episodes with Oral
19 episodes with Oral
15 episodes with Oral
18 episodes with Oral
46 episodes with Oral
20 episodes with Oral
21 episodes with Oral
23 episodes with Oral
31 episodes with Oral
18 episodes with Oral
30 episodes with Oral
13 episodes with Oral
50 episodes with Oral
19 episodes with Oral
14 episodes with Oral
18 episodes with Oral
18 episodes with Oral
19 episodes with Oral
26 episodes with Oral
14 episodes with Oral
17 episodes with Oral
38 episodes with Oral
8 episodes with Oral
12 episodes with Oral
24 episodes with Oral
9 episodes with Oral
In this episode of the Science of Skin podcast, Dr. Ted Lain interviews Dr. Matt Zirwas, a leading expert in dermatology, focusing on the latest advancements in treatments for atopic dermatitis and psoriasis. They discuss the potential of new drugs targeting the OX40 pathway, innovative drug delivery methods, and the emergence of highly effective oral therapies for psoriasis. The conversation highlights the evolving landscape of dermatological treatments and the exciting prospects for long-term patient outcomes. In this conversation, Dr. Zirwas and Dr. Lain discuss various dermatological treatments, focusing on drug administration, bioavailability, and the efficacy of new medications for conditions like hidradenitis suppurativa and chronic spontaneous urticaria. They explore the implications of PDE4 inhibitors, the challenges of assessing treatment outcomes, and the importance of pain management in patient care. The discussion highlights the evolving landscape of dermatology and the significance of clinical trials in advancing treatment options. To watch this and other episodes, be sure to check out our YouTube page Takeaways: New drugs targeting the OX40 pathway may revolutionize treatment for atopic dermatitis.Innovative drug delivery methods could lead to less frequent dosing for patients.The potential for long-term remission in atopic dermatitis is an exciting prospect.Adverse events in new drugs may correlate with better efficacy.Oral therapies for psoriasis are emerging as a new class of effective treatments.The efficacy of new oral drugs may surpass traditional biologics.The importance of understanding pharmacokinetics in drug efficacy is highlighted.The development of advanced systemic therapies is changing the landscape of dermatology.The future of psoriasis treatment may include drugs that effectively target both skin and joint disease. Drug bioavailability is significantly affected by food intake.PDE4 inhibitors show promise in improving various conditions.Cognitive benefits have been observed with PDE4 inhibitors.Pain management is a critical endpoint in HS treatment.Assessing HS severity is challenging for investigators.New treatments are emerging for chronic spontaneous urticaria.Patient satisfaction is essential in evaluating treatment success.Innovative drugs are changing the landscape of dermatology.Clinical trials are crucial for advancing treatment options.Understanding patient needs is key to effective care. Disclaimer: This podcast is not intended to provide diagnosis, treatment, or medical advice. Content provided in this podcast is for educational purposes only. Please consult with a physician regarding any health-related diagnosis or treatment. See omnystudio.com/listener for privacy information.
Implant placement is one thing, but making sure those implants survive years of chewing forces is another. In this episode, Dr. Grant Stucki welcomes back Florida general dentist Dr. Vic Martel to dive deep into occlusion from an implant perspective. In today's conversation, Dr. Martel explains why implant occlusion is often even more critical than occlusion on natural teeth, how uneven load sharing leads to problems like loose screws, chipped porcelain, bone loss, and even loss of integration, and why surgeons are ultimately at the mercy of their restoring dentists' occlusal skills. He discusses practical guidelines for single posterior implants, angled implants in full-arch cases, maxillary second molars, anterior implants, and zirconia hybrids, as well as how to check occlusion correctly in centric, excursions, and with the patient both reclined and upright. Dr. Martel also shares how to manage bruxers, when to splint restorations, why screws need to be replaced after loosening, and ways frequent maintenance and clear patient instructions can prevent many complications before they start. Tune in now!Key Points From This Episode:How Dr. Martel defines occlusion as “load sharing” in the context of implant dentistry.Why occlusion is critical for natural teeth and how uneven load sharing leads to failures.Hear how to set occlusion for an implant using shim stock in normal closure and clench.Explore how to manage axial and non-axial loading on angled implants in full-arch cases.Steps for checking occlusion and why screw-retained restorations have become his standard.Discover common reasons for loose screws and why the screw often needs to be replaced.Steps for navigating microtrauma on implants, patients who brux, and splint restorations.Typical reasons why certain implants fail and guidelines for anterior implant occlusion.Find out how to distribute forces across implant-supported anterior bridges to avoid load.Unpack how the shift from acrylic hybrids to zirconia has changed occlusal schemes. Learn about the complications from occlusion and why it should be checked frequently.What to tell patients about soreness, looseness, night guards, and regular maintenance. Dr. Martel's final takeaways for preventing occlusion-related implant problems.Links Mentioned in Today's Episode:Dr. Victor Martel on LinkedIn — https://www.linkedin.com/in/victor-martel-dmd-fagd-91431922/ Dr. Victor Martel on Instagram — https://www.instagram.com/drvicmartel/ Dr. Victor Martel Email Address — vicmartel@gmail.com Dr. Victor Martel Phone Number — 561 602 7222 Martel Academy — https://martelacademy.com/ Everyday Oral Surgery Website — https://www.everydayoralsurgery.com/ Everyday Oral Surgery on Instagram — https://www.instagram.com/everydayoralsurgery/ Everyday Oral Surgery on Facebook — https://www.facebook.com/EverydayOralSurgery/Dr. Grant Stucki Email — grantstucki@gmail.comDr. Grant Stucki Phone — 720-441-6059
Support this show: https://esta-pareja.firstory.io/joinLeave a comment and share your thoughts: 贊助台瓜夫妻一杯咖啡，行動支持我們的創作 留言告訴我你對這一集的想法： https://open.firstory.me/user/ckkpgxtrc1dry0866oypwapxf/comments 想諮詢雲飛課程，歡迎加 Line: yunfei1205 ，預約線上諮詢 想了解雲飛西語「線上密集班」課程？按這裡 想了解 2026 年雲飛一般課程、DELE 準備班課程？點這裡看成人團體課程 聰明學好語言必讀：懂語感無痛學好任一種外語 西班牙語教材推薦 雲飛臉書粉絲頁 雲飛西班牙語、華語、師資訓練課程官網 雲飛線上學校預錄型課程 游皓雲 Yolanda 老師個人部落格 洛飛南 Fernando 老師個人部落格 教室地址：
Did God have a language? Did Adam and Eve speak Hebrew—or something else entirely? In this episode of Ask Dr. E, Dr. Michael Easley explores what the Bible reveals about language at creation, the Tower of Babel, and how God communicated with humanity from the very beginning.Walking through Genesis, Hebrew, and the broader family of Semitic languages, Dr. Easley explains why Scripture doesn't give a definitive answer—but does give meaningful insight. From Adam naming the animals to the confusion of languages at Babel and the unity of tongues in Acts 2, this episode connects theology, history, and biblical literacy in a thoughtful and accessible way.Whether you're curious about Hebrew, biblical inspiration, or how oral tradition shaped Scripture before it was written, this conversation invites you to ask better questions—and trust the authority of God's Word.Key Topics Discussed• Did God, Adam, and Eve share a language?• Hebrew and the family of Semitic languages• Language and communication before the Fall• Adam naming the animals in Genesis• The Tower of Babel and the origin of languages• Ethnicities and people groups in Scripture• Acts 2 as the reversal of Babel• Oral tradition before the written Pentateuch• Moses, authorship, and biblical inspiration• Why Scripture leaves room for mysteryChapters00:00 – Introduction00:19 – Did God and Adam share a language?01:25 – What Scripture tells us—and what it doesn't01:52 – Hebrew and Semitic language roots02:40 – Was there a pre-Fall or “holy” language?03:10 – Adam naming the animals04:05 – The Tower of Babel explained04:40 – Acts 2 and the unity of language05:23 – Oral tradition and writing the Pentateuch06:15 – Inspiration and authority of Scripture06:57 – Final thoughts If you've got a question for Dr. Easley, call or text us your question at 615-281-9694 or email at question@michaelincontext.com.
Key Episode TakeawaysOral Wegovy is real, but it's not “just a pill version of the shot.” Absorption rules, dosing schedules, and patient selection matter a lot more than most headlines suggest.Switching from injections to oral GLP-1s requires a plan. The transition isn't one-size-fits-all, and dose timing, GI tolerance, and expectations need to be managed carefully.Weight regain after stopping GLP-1s is common, but not universal. SURMOUNT-4 data shows large variability, reinforcing that biology, not willpower, drives outcomes.Maintenance matters as much as weight loss. Some patients need continued therapy at lower doses, while others may maintain with lifestyle plus strategic medication use.Stopping abruptly is usually the worst approach. Gradual transitions and realistic long-term strategies reduce rebound weight gain.GLP-1s are chronic disease tools, not short-term fixes. Treating obesity like hypertension or diabetes leads to better outcomes and fewer surprises. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this episode, you will listen to a passage in Hindi and we will train you to comprehend it and respond to questions based on it. And we'll review some sentence structures like- Do you have a meeting with someone today?' and 'Will you take a while to reach the office today?'. Kindly support us & get access to the transcript of this podcast as well as the detailed worksheet based on this podcast with more vocabulary and weekly Exercise worksheets on Patreon : https://www.patreon.com/learnhindionthego To take a free trial for online Hindi lessons visit: https://learnhindischool.com Find out more at https://learn-hindi-on-the-go.pinecast.co This podcast is powered by Pinecast.
On episode #98 of the Infectious Disease Puscast, Daniel reviews the infectious disease literature for the weeks of 1/1/26 – 1/14/26. Host: Daniel Griffin Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Rhinovirus-Associated Lower Respiratory Tract Infection in Hospitalized Adult Patients: A Retrospective Cohort Study (JID) Demise of the Milwaukee Protocol for Rabies (CID) Reply to Willoughby on Demise of the Milwaukee Protocol for Rabies (CID) Bacterial Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Introduction and Methods (CID) Reassessing the 2023 International Society for Cardiovascular Infectious Diseases Duke clinical criteria for infective endocarditis: Impact of excluding fever and updating diagnostic definition (CID) The diagnostic accuracy of procalcitonin for community-acquired bacteremia: an updated systematic review and meta-analysis (CMI: Clincal Microbiology and Infection) Noninferiority of One HPV Vaccine Dose to TwoDoses (NEJM) About the wastewater program (Colorado: Department of Public & Environment) Notes from the Field: Wastewater Surveillance for Measles Virus During a Measles Outbreak — Colorado, August 2025 (CDC: MMWR) Notes from the Field: Retrospective Analysis of Wild-Type Measles Virus in Wastewater During a Measles Outbreak — Oregon, March 24–September 22, 2024 (CDC:MMWR) Fungal The Last of US Season 2 (YouTube) Candidozyma auris (formerly Candida auris): Resistant, long-lasting, and everywhere (CMI: Clincal Microbiology and Infection) Long-range air dispersal as an important source of environmental contamination in Candida auris clustering: possible infection control implication (Infection Control & Hospital Epidemiology) Parasitic Dermlite Dermatoscopes (dermatoscopes.com) Oral ivermectin versus 5% permethrin cream to treat children and adults with classic scabies: multicentre, assessor blinded, cluster randomised clinical trials (BMJ) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.
Let's be honest... the oral glucose tolerance test is nobody's idea of a good time. Gulping down a neon-sweet drink, feeling gross, and then anxiously waiting for numbers? Hard pass.Today we're breaking down alternatives to the oral glucose tolerance test — what actually gives us useful data, who these options are best for, and why one-size-fits-all testing doesn't belong in modern healthcare.LOOKING FOR HOLISTIC PRECONCEPTION AND PRENATAL SUPPORT:Find out more about the Holistic Mama Collective here.FIND NAT BELOW:Website - https://nataliekdouglas.com/Instagram - https://www.instagram.com/natalie.k.douglasBook a Free Assessment Call - https://NatalieKDouglas.as.me/?appointmentType=50255874EndoNourish - Endometriosis and Adenomyosis Guide - https://nataliekdouglas.com/endonourish-holistic-endometriosis-adenomyoisis-care-guide/SacredSeeds - Preconception Care Guidehttps://nataliekdouglas.com/preconception-care-guide/PCOS Wellness Guidehttps://nataliekdouglas.com/pcos-holistic-guide/Thyroid Rescue - Self guided programhttps://nataliekdouglas.com/thyroid-rescue/Coming Off The Pill/IUD Holistic Guidehttps://nataliekdouglas.com/coming-off-the-pill-mini-course/PMS/PMDD Natural Solutons Masterclass https://nataliekdouglas.com/pms-pmdd-natural-solutions-masterclass/Restore and Nourish Gut Reset - https://nataliekdouglas.com/restore-nourish-gut-reset/Perimenopause Masterclass -https://nataliekdouglas.com/perimenopause-masterclass-holistic-toolkit/Become a one-to-one clienthttps://nataliekdouglas.com/1-1-naturopathic-nutrition-consultations/FIND AMIE BELOW:Book a Free Assessment Call: https://p.bttr.to/3yBdmu3 Book Yourself In: https://l.bttr.to/ZDxWOWebsite - https://whatthenaturopathsaid.com Instagram - https://www.instagram.com/thatnaturopathJoin the mailing list - https://elysium-clinic-of-natural-medicine.ck.page/69663ce14a
Bathing frequency doesn't matter in AD -Tapering down JAKs in AD -Oral plasma cell mucositis -IL sodium thiosulfate for calcinosis cutis - Check out Luke's Urticaria CME experience! aaaaicsu.gathered.com/invite/KQe1wPZbJY Learn more about the U of U Dermatology ECHO model! physicians.utah.edu/echo/dermatology-primarycare Want to donate to the cause? Do so here! Donate to the podcast: uofuhealth.org/dermasphere Check out our video content on YouTube: www.youtube.com/@dermaspherepodcast and VuMedi!: www.vumedi.com/channel/dermasphere/ The University of Utah's Dermatology ECHO: physicians.utah.edu/echo/dermatology-primarycare - Connect with us! - Web: dermaspherepodcast.com/ - Twitter: @DermaspherePC - Instagram: dermaspherepodcast - Facebook: www.facebook.com/DermaspherePodcast/ - Check out Luke and Michelle's other podcast, SkinCast! healthcare.utah.edu/dermatology/skincast/ Luke and Michelle report no significant conflicts of interest… BUT check out our friends at: - Kikoxp.com (a social platform for doctors to share knowledge) - www.levelex.com/games/top-derm (A free dermatology game to learn more dermatology!
Send a Text Message. Please include your name and email so we can answer you! Please note, this does not subscribe you to our email list, it's just to answer if you have a questions for us. We finally have the first-ever FDA-approved oral GLP-1 for treating obesity, and it's a much bigger deal than the headlines suggest…In this episode, I'm joined by Joseph Zucchi, PA, a clinical supervisor at a weight management clinic who lives and breathes the data behind obesity care. We break down oral Wegovy in practical terms: the real weight loss data, how it compares with weekly injections, why it's different from Rybelsus, and who it's best suited for. We also cover cost, insurance disruptions, and what to realistically expect if you're considering a switch.If you're trying to make sense of your options in a fast-changing landscape, whether due to coverage changes, injection concerns, or simple confusion — this conversation helps break it all down using real data.ReferencesConnect with Joseph Zucchi, PATransition Medic Medical Weight LossLinkedinAudio Stamps01:42 – Meet Joseph Zucchi, PA, clinical supervisor at a comprehensive weight management clinic with an on-site food store.04:35 – What is oral Wegovy and how does it compare to injectable semaglutide in terms of efficacy and weight loss?07:21 – The reformulation that makes oral Wegovy different from Rybelsus and why absorption matters.10:22 – How to take oral Wegovy correctly: timing, dosing instructions, and common mistakes to avoid.12:02 – Who should consider oral Wegovy and who might be better off sticking with injections?13:45 – Side effects, dosing transitions, and what to expect when switching from injectable to oral.22:03 – The importance of specialized care: why working with a weight management expert improves outcomes.24:00 – Pricing, insurance coverage challenges, and accessibility of oral Wegovy in 2026.All of the information on this podcast is for general informational purposes only. Please talk to your physician and medical team about what is right for you. No medical advice is being on this podcast. If you live in Indiana or Illinois and want to work with doctor Matthea Rentea, you can find out more on www.RenteaClinic.com Not Sure Where to Start With the Podcast? I've Got You.Get my free Podcast Roadmap—a simple guide to help you find the episodes that matter most to your journey. Whether you're on GLP-1s, navigating plateaus, or just starting out, there's something here for you.Support the show
Welcome to Teeth & Titanium, Episode 62, “Permanent Bad Insurance” This episode features: Current Events- Oscar's math skills- Spotify Wrapped New Years Resolutions Fan Mail- McGill medical rotation update- Joey from Brampton Resident reminder - Local Anesthetic Toxicity Journal Club- Federal Student Loan Changes Uniquely Impact 6-Year Oral and Maxillofacial Surgery Residents- Rates and Determinants of Prosthodontic Rehabilitation After Segmental Jaw Surgery- Naloxone Coprescribing in Oral and Maxillofacial Surgery: An Opportunity for Harm Reduction? Your personal Finance Drill from PWL Capital, “Whole Life Insurance”- Brady Plunkett Senior Wealth Advisor, Portfolio Manager, CFP®, CIM® Recommendations- Greatest movie of all time Be sure to subscribe so you never miss an episode! Apple / Spotify / Google / Online links Thanks to the CAOMS and PWL for their continued support of this podcast. https://www.caoms.com. PWL Capital; https://pwlcapital.com/ If you would like to contact us, be a guest, or would like to submit a topic for Resident Reminder or Journal club, please email us at: teethandtitaniumOMFS@gmail.com Hosted by Dr. Wendall Mascarenhas & Dr. Oscar DalmaoProduced by Dr. Brad W. Ray Articles/Books cited in this episode: Morgan CD, Borbiev ST, Peacock ZS. Federal Student Loan Changes Uniquely Impact 6-Year Oral and Maxillofacial Surgery Residents. J Oral Maxillofac Surg. 2026 Jan;84(1):9-10. Idrissi Janati A, Nizar Beema A, Gigliotti J, Makhoul N, El-Hakim M, Karra N. Rates and Determinants of Prosthodontic Rehabilitation After Segmental Jaw Surgery. J Oral Maxillofac Surg. 2026 Jan;84(1):127-137. Sung KE, Wang TT, Keith DA, Hajibandeh JT. Naloxone Coprescribing in Oral and Maxillofacial Surgery: An Opportunity for Harm Reduction? J Oral Maxillofac Surg. 2026 Jan;84(1):6-8.
I never thought I'd be glued to my screen tracking court battles like they're the Super Bowl, but here we are in mid-January 2026, and President Donald Trump's legal showdowns are dominating the dockets from Hawaii to the Supreme Court steps in Washington, D.C. Just this past week, as the Supreme Court wrapped up arguments in cases like Chevron USA Inc. v. Plaquemines Parish in Louisiana and Little v. Hecox, all eyes shifted to Trump's escalating clashes with federal agencies and old foes. On Friday, January 16, SCOTUSblog reported the justices huddled in private conference, voting on petitions that could add more Trump-related fireworks to their calendar.Take Trump v. Cook, heating up big time. President Trump tried firing Lisa Cook, a Democratic holdover on the Federal Reserve Board of Governors, back in August 2025, calling her policies a mismatch for his America First agenda. U.S. District Judge Cobb in Washington blocked it, and the D.C. Circuit Court of Appeals upheld her ruling 2-1. Now, the Trump administration, led by Solicitor General D. John Sauer, is begging the Supreme Court to intervene. Oral arguments hit Wednesday, January 21, at 10 a.m. in the Supreme Court building, with Paul Clement—former Solicitor General under George W. Bush—defending Cook. Sauer blasted the lower courts as meddling in presidential removal power, echoing fights in Trump v. Slaughter, where the Court already chewed over firing FTC Chair Lina Khan's allies like Alvaro Bedoya last December. Dykema's Last Month at the Supreme Court newsletter calls it a direct shot at the 1935 Humphrey's Executor precedent, questioning if Congress can shield multi-member agency heads from the president's axe.It's not just agency drama. E. Jean Carroll, the former Elle writer who won $5 million defaming her after a jury found Trump liable for sexually abusing her in a Bergdorf Goodman dressing room in the 1990s, just urged the Supreme Court to swat down his latest petition. ABC News covered her filing this week, where she argues U.S. District Judge Lewis Kaplan in New York got evidence rules spot-on—no reversal needed.And that's barely scratching the surface. The Court's January calendar, straight from supremecourt.gov, lists Trump v. Cook smack in the middle, following Wolford v. Lopez on Tuesday, January 20—a Second Amendment tussle over Hawaii's law banning guns on private property open to the public without the owner's okay. Axios predicts 2026 bombshells like Trump v. Barbara on his executive order gutting birthright citizenship under the 14th Amendment, potentially stripping citizenship from kids of undocumented immigrants born on U.S. soil. Then there's Learning Resources v. Trump, challenging his national emergency tariffs on foreign goods—Axios says a loss could force $100 billion in refunds and crimp his trade wars.Over in lower courts, Just Security's litigation tracker logs fresh salvos: challenges to Executive Order 14164 jamming January 6 convicts into ADX Florence supermax in Colorado, and suits against orders targeting law firms like Perkins Coie, Jenner & Block, and WilmerHale for alleged anti-Trump bias. Lawfare's tracker flags national security spins on these executive actions. Even California Republicans appealed a Los Angeles panel's smackdown of their gerrymander claims against Governor Gavin Newsom's maps to the Supreme Court this week, per SCOTUStoday.These cases aren't just legal jargon—they're power plays reshaping the presidency, from Fed independence to gun rights and citizenship. As Trump posts fire on Truth Social about "evil, American-hating forces," the justices gear up for a term that could torch decades of precedent.Thanks for tuning in, listeners—come back next week for more. This has been a Quiet Please production, and for more, check out Quiet Please Dot A I.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI
HEALTH NEWS Probiotics emerge as a potent tool against depression and anxiety Altered microbiome: Oral bacteria play a role in chronic liver disease, study reveals Health issues linked to cosmetic jab complications From yoga to awe walks: Many paths lead to better mental health, largest analysis of well-being interventions finds Weight loss drugs may cause nutritional deficiencies without proper guidanc Probiotics emerge as a potent tool against depression and anxiety University of Calgary (Canada), January 14 2026 (Natural News) For decades, the standard pharmaceutical approach to treating depression and anxiety has dominated treatment options, despite significant drawbacks including delayed effects, debilitating side effects and high relapse rates. Now, compelling new research is challenging this paradigm by pointing to a surprising source of relief: the gut. A comprehensive scientific analysis, synthesizing data from over 1,400 clinically diagnosed patients, reveals that probiotics—beneficial bacteria readily available as supplements—can produce substantial reductions in both depressive and anxious symptoms. The analysis major findings include: A major analysis of 23 clinical trials finds probiotics can significantly reduce symptoms of depression and anxiety in clinically diagnosed patients. The benefits, appearing within 4-8 weeks, were comparable to some conventional antidepressants but without the same side-effect profile. The gut-brain axis, a communication network largely ignored by conventional psychiatry, is central to understanding this connection. Single-strain probiotic supplements, particularly certain Lactobacillus and Bifidobacterium species, showed the strongest mental health effects. This research supports a holistic view of mental wellness, where gut health is a foundational component of treatment. Altered microbiome: Oral bacteria play a role in chronic liver disease, study reveals Technical University Munich (Germany), January 15 2026 (Medical Xpress) Each year, more than two million people die from advanced chronic liver disease (ACLD). Previous research has linked gut microbiome disruptions to this condition and suggested that bacteria typically found in the mouth may colonize the gut. A new study published in Nature Microbiology now shows that identical bacterial strains occur in both the mouth and gut of patients with advanced chronic liver disease and also reveals a mechanism by which oral bacteria affect gut health. The researchers also found that this process coincides with worsening liver health. Researchers analyzed bacterial populations in saliva and stool samples from patients. The team found that both the gut and oral microbiome undergo significant changes as liver disease worsened, where changes to the oral microbiome were already detectable at earlier disease stages. In healthy individuals, bacterial communities differ substantially between body sites. In patients with liver disease, however, oral and gut microbiomes became increasingly similar as the disease progressed and nearly identical bacterial strains were recovered from the mouth and gut of patients. "These strains are typically found in the mouth and are rarely present in the healthy gut. However, we observed increases in the absolute abundances of these oral bacteria in patients with advanced chronic liver disease. This strongly suggests that these bacteria translocate from the mouth and colonize the gut," explains Melanie Schirmer, Professor of Translational Microbiome Data Integration at TUM. Health issues linked to cosmetic jab complications Anglia Ruskin University (UK), January 9 2026 (Eurekalert) Patients with chronic illnesses face a significantly higher risk of complications from cosmetic botulinum toxin injections, commonly known as Botox, according to a major UK study. Researchers from Anglia Ruskin University (ARU) surveyed 919 adults who had received botulinum toxin treatments for aesthetic reasons. The study, published in Aesthetic Surgery Journal, is the largest of its kind to have been carried out in the UK. Botulinum toxin injections are among the UK's most popular cosmetic procedures, with an estimated 900,000 treatments performed every year. Researchers found that underlying conditions such as type 1 diabetes, thyroid disorders, chronic migraine and skin disease dramatically increase the likelihood of adverse effects. According to the study, people with type 1 diabetes were 92 times more likely to experience nausea after treatment compared to those without the condition. Those with thyroid disorders and chronic migraine sufferers had an approximately 10-fold increase in the risk of nausea. Other complications associated with pre-existing conditions included headaches, bruising, muscle weakness and persistent eyelid droop (ptosis). Patients with cataracts were 30 times more likely to report headaches, and those with prior injuries had a 21-fold increased risk of losing facial expression. From yoga to awe walks: Many paths lead to better mental health, largest analysis of well-being interventions finds Swansea University (UK), January 15 2026 (Medical Xpress) New research by Swansea experts has provided the largest ever comparison of well-being-focused interventions delivered to adults. The team reviewed 183 randomized controlled trials, representing almost 23,000 participants, and evaluated 12 categories of interventions ranging from psychological, physical, mind–body, and nature-based approaches to find out more. Their research was the first interdisciplinary comparison carried out across psychological, physical, mind-body and environmental interventions. The study gives an integrated view of how different disciplines contribute to well-being. By focusing on general adult samples rather than clinical groups, it provides evidence that will be relevant to developing public health, education, workplace well-being, and community programs. The researchers' key findings were: Most interventions improved well-being compared with inactive control groups; Strongest effects were found for combined exercise plus psychological interventions (for example, awe walks or meditation combined with walking); Mind–body interventions showed consistently moderate, reliable effects; Exercise alone produced similar benefits to many psychological interventions; and, Positive psychology interventions—both single-component and multicomponent—were also effective. The analysis shows that there is no single route to improving well-being. Mindfulness, compassion-based approaches, yoga, exercise and positive psychology interventions all showed moderate benefits compared with control groups, and combining physical activity with psychological interventions appeared particularly promising. Weight loss drugs may cause nutritional deficiencies without proper guidance University College London & Cambridge, January 7 2026 (News-Medical) People prescribed the new generation of weight loss drugs may not receive sufficient nutritional guidance to support safe and sustainable weight loss, leaving them vulnerable to nutritional deficiencies and muscle loss, say experts at UCL and the University of Cambridge. In research published today in Obesity Reviews, the team found a lack of robust evidence surrounding nutritional advice and support and the impact this has on factors such as calorie intake, body composition, protein adequacy, and patient experiences. Weight loss drugs such as semaglutide and tirzepatide – available under brand names including Ozempic, Wegovy and Mounjaro – mimic the naturally-occurring hormone glucagon like peptide-1 (GLP-1), released into the blood in response to eating. The drugs suppress appetite, increase a feeling of being full, and reduce food cravings. These drugs can reduce calorie intake by between 16-39 %, making them a powerful tool to help people living with obesity and being overweight. However, there has been little research to examine their impact on diet quality, protein intake, or adequacy of micronutrients (vitamins and minerals). The researchers identified just 12 studies that looked at nutrition and diet alongside treatment with semaglutide or tirzepatide. Given the widespread – and increasing – use of these medications and the urgency of providing advice to individuals using the drugs, there was insufficient evidence from the studies to recommend strict low-fat diets to complement the weight loss drugs. Some observational studies found that people on the treatments often consumed excessive levels of total and saturated fat. These medications are transforming obesity care, but we know very little about how they shape people's daily lives, including changes in appetite, eating patterns, wellbeing, and quality of life.
In this week's roundup, JAMA Medical News Director Jennifer Abbasi and Associate Managing Editor Kate Schweitzer discuss "What to Know About the Wegovy Pill for Obesity" and more. Related Content: What to Know About the Wegovy Pill for Obesity
In this interview we discuss The Unraveling Heart: Women's Oral Poetics and Literary Vernacularization in Marathi (Columbia UP, 2025). Women's songs of the grind mill are among the oldest oral traditions in South Asia. They have been sung to accompany a daily household labor, making flour using a stone hand mill, for many centuries. Even today, grind mill songs are still well known in Maharashtra, testifying to the endurance of a remarkable genre. Yet these songs have long been understood through sociological or anthropological lenses, treated as entirely separate from literary culture. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network
In this enlightening conversation, Dr. Sanda Moldovan and Nam Lee delve into the world of acupuncture and its profound impact on holistic health, particularly in the realms of fertility and women's health. Nam shares her journey from engineering to becoming a licensed acupuncturist, emphasizing the importance of posture, stress management, and the unique approaches of traditional Chinese medicine compared to Western practices. The discussion highlights practical tips for improving egg quality, managing anxiety, and the significance of oral health in fertility. Nam also shares insights on herbal medicine and daily habits that can support hormonal balance, making this episode a treasure trove of knowledge for anyone interested in holistic health.Want to see more of The Holistic Dentistry Show? Watch our episodes on YouTube! Do you have a mouth- or body-related question for Dr. Sanda? Send her a message on Instagram! Remember, you're not healthy until your mouth is healthy. So take care of it in the most natural way. Key Takeaways: Acupuncture is a powerful tool for holistic health. Posture plays a crucial role in overall well-being. Fertility challenges can be addressed through acupuncture. Traditional Chinese medicine offers a hopeful perspective on fertility. Stress management is essential for reproductive health. Men's health is equally important in fertility discussions. Herbal medicine complements acupuncture in treatment plans. Oral health can impact fertility outcomes. Daily habits can significantly influence hormonal balance. Acupuncture can effectively manage anxiety and improve mental health. Chapters (00:00) Introduction to Acupuncture and Holistic Health (03:02) The Journey to Becoming an Acupuncturist (05:50) Fertility and Acupuncture: A Unique Approach (08:49) Understanding Acupuncture: Mechanisms and Benefits (11:57) The Connection Between Posture and Health (14:55) Traditional Chinese Medicine vs. Western Medicine in Fertility (17:59) The Role of Age in Fertility and Acupuncture (23:28) Natural Conception at 45: A Success Story (24:40) Improving Egg Quality: Key Strategies (29:10) Men's Health: Enhancing Sperm Quality (30:57) Acupuncture and Anxiety Management (35:30) Recognizing Hormonal Imbalances (36:57) The Role of Oral Health in Fertility (37:57) Detoxification and Acupuncture (40:11) Herbal Medicine: A Natural Approach (44:11) Daily Habits for Hormonal Balance Guest Info: Social: @lee_acupuncture Links: www.leeacupuncture.com Connect With Us: AskDrSanda | YouTube BeverlyHillsDentalHealth.com | Instagram DrSandaMoldovan.com | Instagram Orasana.com | Instagram
In this interview we discuss The Unraveling Heart: Women's Oral Poetics and Literary Vernacularization in Marathi (Columbia UP, 2025). Women's songs of the grind mill are among the oldest oral traditions in South Asia. They have been sung to accompany a daily household labor, making flour using a stone hand mill, for many centuries. Even today, grind mill songs are still well known in Maharashtra, testifying to the endurance of a remarkable genre. Yet these songs have long been understood through sociological or anthropological lenses, treated as entirely separate from literary culture. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/literary-studies
In this interview we discuss The Unraveling Heart: Women's Oral Poetics and Literary Vernacularization in Marathi (Columbia UP, 2025). Women's songs of the grind mill are among the oldest oral traditions in South Asia. They have been sung to accompany a daily household labor, making flour using a stone hand mill, for many centuries. Even today, grind mill songs are still well known in Maharashtra, testifying to the endurance of a remarkable genre. Yet these songs have long been understood through sociological or anthropological lenses, treated as entirely separate from literary culture. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/south-asian-studies
One on One Video Call W/George https://tidycal.com/georgepmonty/60-minute-meetingSupport the show:https://www.paypal.me/Truelifepodcast?locale.x=en_USKeywordsbeauty, health, SOD, immune system, dermatology, Francois Vix, beauty industry, skincare, natural products, holistic healthSummaryIn this enlightening conversation, George and Francois Vix delve into the intricate relationship between beauty, health, and the immune system. Francois shares his extensive experience in the beauty industry, emphasizing that true beauty transcends mere decoration and is deeply rooted in health and well-being. The discussion highlights the significance of superoxide dismutase (SOD) as a critical enzyme that plays a vital role in maintaining cellular health and beauty. They explore various applications of SOD, from dermatology to athletic performance, and address the importance of a holistic approach to beauty that combines science with human experience.TakeawaysBeauty is not just decoration; it's a negotiation with time.Health is more important than beauty, as true beauty stems from health.SOD (superoxide dismutase) is a critical enzyme for cellular health.The immune system plays a foundational role in achieving beauty.Beauty is a reflection of a life well lived, not just physical appearance.SOD can help with various health issues, including skin conditions and athletic recovery.Combination therapy, including nutraceuticals and topical treatments, is essential for optimal results.Generosity and love are among the most beautiful aspects of life.The mirror reflects honesty, prompting self-reflection and growth.Clinical trials and scientific research are crucial for validating health products. TitlesThe Essence of Beauty: A Deeper ConversationFrancois Vix: A Journey Through the Beauty IndustrySound bites"Beauty is biology in motion.""SOD is the enzyme of life.""We can help with recovery."Chapters00:00 The Essence of Beauty: A Negotiation with Time02:28 Francois Vix: A Journey Through the Beauty Industry10:22 Beauty Beyond Decoration: Health and Radiance14:31 The Science of SOD: A Breakthrough in Beauty and Health38:17 The Immune System: The Foundation of True Beauty45:31 Vitiligo and Melasma: The Duality of Skin Conditions52:24 The Impact of Vitiligo on Life and Identity53:42 Combining Ingredients for Optimal Skin Health55:35 The Role of SOD in Dermatology and Aesthetic Treatments57:12 SOD and Its Potential in Cancer Treatment01:01:17 Reconstructive Surgery and Recovery Enhancements01:06:30 SOD in Sports Medicine and Athletic Recovery01:09:42 The Focus on Dermatology and Aesthetic Medicine01:11:00 Philosophical Perspectives on Aging and Beauty01:17:40 The Changing Landscape of Beauty in the Digital Age01:19:35 The Importance of Patience in Nutraceuticals01:20:19 Oral vs. Topical Products in Beauty01:21:18 Ethics in the Beauty Industry01:24:29 The Intersection of Science and Human Experience01:27:45 Finding Beauty Beyond Appearancehttps://www.glisodin.com/ One on One Video call W/George https://tidycal.com/georgepmonty/60-minute-meetingSupport the show:https://www.paypal.me/Truelifepodcast?locale.x=en_US
Real Life We kick things off with a round of Real Life check-ins, because apparently none of us are allowed to simply exist quietly. Ben opens with Bedroom Talk with Ben Lawless, which is exactly as awkward, candid, and vaguely alarming as it sounds. No further clarification is offered, nor requested. Devon reports that snowboarding with his kids was actually great. No injuries, no disasters—just genuine fun on the mountain, which frankly feels suspicious but we'll allow it. He also shares that he's been practicing guitar for an hour a day, really locking in on technique. That means working through BPMs, tightening up tapping and sweeping, and grinding away at the Blackened solo like a man possessed. Progress is being made, fingers are suffering, and discipline is winning (for now). Steven talks about Hawaii, which lands somewhere between "kinda cool" and "why did we do this to ourselves." The travel was awful, the resort was pretty great, and Moana… apparently isn't Moana anymore? We don't resolve this, but we are confident Disney has a lot to answer for. Ben also brings in Blippo+, a surreal streaming service that feels like channel surfing through an alternate universe. If you're curious (or concerned), you can explore it directly at https://blippo.plus/ or read more context over at The A.V. Club: https://www.avclub.com/blippo-makes-art-out-of-channel-surfing. Future or Now In Future or Now, Ben highlights a sobering study out of Japan linking poor oral health in older adults to higher mortality rates and increased need for long-term care. The research, conducted by Osaka Metropolitan University and the Institute of Science Tokyo, suggests brushing and dental care might matter more than we'd like to admit. You can read the full breakdown via The Japan Times: https://www.japantimes.co.jp/news/2026/01/05/japan/science-health/elderly-dental-hygiene/ Devon follows up with This Week in Space, reacting to the news that the U.S. has effectively killed NASA's Mars Sample Return Mission. What happens now? Confusion, disappointment, and a lot of unanswered questions. The full story is covered here: https://www.iflscience.com/us-just-killed-nasas-mars-sample-return-mission-so-what-happens-now-82148 Book Club This week's Book Club pick is "The Janitor in Space" by Amber Sparks, a short story that sparked very different reactions around the table. Steven enjoyed it, Ben didn't care for it at all, and Devon—rather than choosing a side—asked ChatGPT to turn it into a song, which may be the most Devon response possible. You can read the story yourself here: https://americanshortfiction.org/janitor-space/ Looking ahead, next week's selection is Ted Chiang's "What's Expected of Us", originally published in Nature (July 7, 2005). We'll be digging into free will, determinism, and the uncomfortable feeling that the universe might already know what you're about to do. As always, thanks for listening, reading, and continuing to question whether brushing your teeth might actually save your life.
Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Ever wondered what's really changing the game in weight loss treatments? Well, oral Wegovy might be it. Unlike other GLP-1 medications that require weekly injections, this is the first long-term weight-loss pill in its class. For many people, taking a daily tablet just feels way more doable—it's flexible, lowers mental barriers, and makes managing weight something that can actually fit into everyday life.In this episode, my guest is Joseph “Joe” Zucchi, a physician assistant and personal trainer with over a decade of experience in obesity medicine. He leads a multidisciplinary team in Salem, New Hampshire, helping patients achieve sustainable weight loss through a mix of fitness, nutrition, and medical care. Joe has been recognized for his work—leading his center to win awards, writing for outlets like the Wall Street Journal, MedPage Today, Healthline, and Doximity, and advocating for patient access to treatments like Zepbound. His insights make it clear that oral Wegovy isn't just another pill—it's part of a thoughtfully designed, patient-centered approach to obesity care.In this episode, we break down everything you need to know, including GLP-1 medications in simple terms, the future of oral Wegovy, what counts as success on the pill, side effects to expect, the technology behind it, how to take it properly, safely transitioning between pill and injection, who benefits most (and who should avoid it), and cost, coverage, and what to expect in 2026. If you've been curious about how oral Wegovy works and whether it could be right for you, this episode walks through it all in practical, real-world terms.Connect with Mr. Zucchi:Linkedin: Joseph Zucchi, PA-CX: JPZfitness Instagram: transitionweightlossConnect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com
What new advancements are actually coming in diabetes care in 2026 and what's in store in the near future? In this episode, Dr. Steve Edelman and Dr. Jeremy Pettus both take a look at the diabetes treatments and technologies they believe are most likely to arrive in 2026.Together, they walk through emerging therapies for both type 1 and type 2 diabetes, focusing on developments that are no longer theoretical but actively moving through late-stage trials and regulatory review. The conversation covers disease-modifying treatments, next-generation medications, and technology advances that could meaningfully change daily diabetes management.Key Topics: • Disease-Modifying Therapies for T1D: Preserving beta cell function after T1D diagnosis and why this represents a major shift in treatment goals.• New Medications for Type 2 Diabetes: Oral GLP-1s, dual- and triple-agonist therapies, and what they may offer beyond current options.• GLP-1s in Type 1 Diabetes: Where the research stands, off-label use today, and what future approvals could look like.• Once-Weekly Basal Insulin: Why it's promising for type 2 diabetes and who it's best suited for.• Inhaled Insulin Updates: New dosing guidance and expanded use cases.• Continuous Ketone Monitoring: How this technology could improve safety and open doors for additional therapies in T1D.• Cure-Oriented Research: Stem cell and gene therapy approaches that aim to restore insulin production.• The Big Picture in 2026: Why 2026 represents real momentum — and what it could mean for access, outcomes, and quality of life. ★ Support this podcast ★
Guest: Jason Auerbach (Bloody Tooth Guy) https://bloodytoothguy.com/ Host: Serv Wahan https://www.drwahan.com/ keywords oral surgery, social media, dentistry, patient care, dental education, sedation techniques, corporate dentistry, private practice, dental instruments, dental technology, bloody tooth guy, Jason Auerbach, Dr. Wahan, Serv Wahan, Max surgical specialty management, riverside oral surgery, om3surgery, Seattle oral surgeon, new jersey oral surgeon summary In this engaging conversation, Serv Wahan MD, DMD, and Jason Auerbach, known as Bloody Tooth Guy, delve into the evolution of social media in dentistry, the challenges posed by algorithms and censorship, and the importance of documentation for dental professionals. They discuss teaching methodologies, ergonomics in practice, and the role of technology in modern dentistry. Auerbach shares his journey to becoming a dentist, the shift from private practice to corporate dentistry, and the evolution of sedation techniques. The conversation concludes with personal insights and reflections on the future of dentistry. takeaways Social media has transformed how dental professionals share knowledge. Documentation is crucial for self-assessment and improvement in dentistry. Teaching is a vital part of the dental profession, enhancing learning for all. Ergonomics and patient positioning are essential for long-term health in practice. The right instruments can significantly impact surgical outcomes. Technology, like CBCT, has revolutionized dental procedures. The journey to becoming a dentist is often influenced by key individuals. Corporate dentistry is on the rise, affecting private practices. Sedation techniques have evolved, improving patient care. Oral maxillofacial surgery is a rewarding specialty that can inspire future generations. titles The Rise of Bloody Tooth Guy Navigating Social Media in Dentistry Sound Bites "I started Bloody Tooth Guy February 20th." "People love to see it, so I'm happy to do it." "A bite block is 101." Chapters 00:00 Introduction to Bloody Tooth Guy 03:03 The Evolution of Social Media in Dentistry 06:00 The Importance of Documentation in Dental Practice 09:04 Teaching and Learning in Dentistry 12:00 Ergonomics and Patient Positioning 15:03 Instruments and Techniques for Extractions 17:53 Personal Journey to Dentistry 28:55 Early Days in Dentistry 34:41 Advancements in Imaging Technology 39:50 Evolution of Sedation Practices 46:45 The Shift Towards Corporate Dentistry 52:25 The Future of Private Practice 56:24 Reflections on Oral Surgery and Music
The first highly effective oral GLP-1 weight loss medication is here. In this episode, Lisa Oldson, MD breaks down the FDA-approved PILL version of semaglutide (oral Wegovy), how GLP-1 receptor agonists work for weight loss, expected results, side effects, cost, and who qualifies for these medications. She also discusses why weight loss medication is not “cheating,” how GLP-1 oral meds compare to injectables, and the World Health Organization's new recommendations supporting long-term use of GLP-1 medications for excess weight. If you're curious about GLP-1 weight loss pills, obesity treatment, and evidence-based approaches to long-term health, this episode is for you.You'll learn:What's new about ORAL (pill form) WegovyWhy weight loss medication is not cheatingHow the brain regulates weightHow GLP-1 medications workMedication + lifestyle: not either / orThanks for listening! If you'd like more support during your SMART weight loss & health focused journey, sign up for our FREE newsletter, or check out our program at: www.SmartWeightLossCoaching.com. We would love to help you reach your happy weight, and transform the way you talk to yourself about your body and the number on the scale. Negative thoughts about yourself don't have to take up so much brain space, and we'd be honored to help you reframe those thoughts. Also…We'd be grateful if you'd follow us and share our podcast with your friends & family. We're here to help you improve your health, live longer, healthier, and lose weight the SMART way! This episode was produced by The Podcast Teacher: www.ThePodcastTeacher.com.
Dr. Monty Pal and Dr. Hope Rugo discuss advances in antibody-drug conjugates for various breast cancer types as well as treatment strategies in the new era of oral SERDs for HR-positive breast cancer. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist and vice chair of academic affairs here at the City of Hope Comprehensive Cancer Center, Los Angeles. Today, I'm thrilled to be joined by Dr. Hope Rugo, an internationally renowned breast medical oncologist and my colleague here at City of Hope, where she leads the Women's Cancers Program and serves as division chief of breast medical oncology. Dr. Rugo is going to share with us exciting advances in antibody-drug conjugates (ADCs) that are expanding treatment options in various breast cancer types. She'll also address some of the complex questions arising in the new era of oral SERDs (selective estrogen receptor degraders) that are revolutionizing treatment in the hormone receptor-positive breast cancer space. Our full disclosures are available in the transcript of this episode. Dr. Rugo, welcome, and thanks so much for being on the podcast today. Dr. Hope Rugo: Thank you. Pleasure to be here. Dr. Monty Pal: So, I'm going to switch to first names if you don't mind. The first topic is actually a really exciting one, Hope, and this is antibody-drug conjugates. I don't know if I've ever shared this with you, but I actually started my training at UCLA, I was a med student and resident there, and it was in Dennis Slamon's lab. I worked very closely with Mark Pegram and a handful of others. This is right around the time I think a lot of HER2-directed therapies were really evolving initially in the clinics. Now we've got antibody-drug conjugates. Our audience is well-familiar with the mechanism there but tell us about how ADCs have really started to reshape therapy for HER2-positive breast cancer. Dr. Hope Rugo: Yeah, I mean, this is a really great place to start. I mean, we have had such major advances in breast cancer just this year, I think really changing the paradigm of treating patients. But HER2-positive disease, we've been used to having sequenced success of new agents. And I think the two biggest areas where we've made advances in HER2-positive disease, which were remarkably advanced this year in 2025, have been in antibody-drug conjugates with trastuzumab deruxtecan and with new oral tyrosine kinase inhibitors (TKIs) that have less of a target on EGFR and more on HER2, so they have an overall more tolerable toxicity profile and therefore a potentially better efficacy in the clinic. At least that's what we're seeing with these new strategies that we couldn't really pursue in the past because of toxicities of the oral TKIs. So, although our topic is ADCs, I'm going to include the TKI because it's so important in our thinking about treating HER2-positive disease. In the metastatic setting, we've seen these remarkable improvements in progression-free and overall survival in the second-line setting with T-DXd, or trastuzumab deruxtecan, compared to T-DM1. And then sequencing ADCs with giving T-DXd after T-DM1 was better than an oral tyrosine kinase or a trastuzumab combination with standard chemotherapy. That was DESTINY-Breast03 and DESTINY-Breast02. So, then we've had other trials since then, and T-DXd has moved into the early-stage setting, which I'll talk about in just a moment. But the next big trial for T-DXd in HER2-positive disease was moving it to the first-line setting to supplant what has become an established treatment for now quite a long time: the so-called CLEOPATRA regimen, which used the combined antibodies trastuzumab, pertuzumab with a taxane as first-line therapy. And then we've proceeded on with maintenance with ongoing HP for patients with responding or stable disease. And we'd seen long-term data showing, you know, at 8 years there was a group of patients whose cancers had never progressed and continued improved overall survival. So, T-DXd was studied in DESTINY-Breast09, either alone or in combination with pertuzumab compared to THP. The patient population had received a little bit more prior treatment, but interestingly, not a lot compared to CLEOPATRA. And they designed the trial to be T-DXd continued until progression with or without pertuzumab versus THP, which would go for six cycles and then stop around six cycles, and then stop and continue HP. Patients who had hormone receptor-positive disease could use hormone therapy, and this is one of the issues with this dataset because, surprisingly in this dataset and one other I'll mention, very few patients took hormone therapy. And even in the maintenance trial, the HER2CLIMB-05, less than 50% took hormone therapy as maintenance. This is kind of shocking to me and highlights an area of really important education, that outcome is improved when you add endocrine therapy for hormone receptor-positive HER2-positive metastatic disease in the maintenance phase, and it's a really important part of treatment. But suffice it to say, you know, you're kind of studying continued chemo versus stopping chemo in maintenance. And T-DXd, as we all expected, in combination with pertuzumab was superior to THP in terms of progression-free survival, really remarkably improved. And you could stop the chemo with toxicity, but most people continued it with T-DXd. Again, not a lot of people got hormone therapy, which is an issue, and you stop the chemo in the control arm. So, this has brought up a lot of interest in trying to use T-DXd as an induction and then go to maintenance, much as we do with the CLEOPATRA regimen with hormone therapy. But it brings up another issue. So first, T-DXd is superior; it's a great treatment. Not everybody needs to have it because we don't know whether it's better to give T-DXd first or second with progression - that we need a little bit longer follow-up. But just earlier this week, interestingly, the third week of December, the U.S. FDA approved T-DXd in the DESTINY-Breast09 approach with pertuzumab. So as I mentioned earlier, there was a T-DXd-alone arm; that arm has not yet reported. So very interesting, we don't know if you need pertuzumab or not. So what about the maintenance? That's the other area where we've made a huge advance here. So, we all want to stop chemo and we want to stop T-DXd. You don't want somebody being nauseated for two years while they're on treatment, and also there's a small number of patients with mostly de novo metastatic HER2-positive disease who are cured of their disease. We'd like to expand that, and I think these new drugs give us the opportunity to improve the number of patients who might be cured from metastatic disease. So the first maintenance study we saw was adding palbociclib, the CDK4/6 inhibitor, to endocrine therapy and HP, essentially. There, we had a remarkable improvement in progression-free survival difference of 15.2 months: 29 to 44 months, really huge. At San Antonio this year, we saw data with this oral tyrosine kinase inhibitor tucatinib, already showed it was great in a triplet, but as maintenance in combination with HP, it showed also a remarkable improvement in progression-free survival. But the numbers were all shifted down. So in PATINA, the control arm was in the 24-month range; here it was the tucatinib-HP arm that was in the 25 months and 16 months for control. So there was a differential benefit in ER-negative and ER-positive disease. So I think we're all thinking that our ideal approach moving forward would be to give T-DXd to most patients, we see how they do, and treat to best response. And then, stop the T-DXd, start HP, trastuzumab, pertuzumab for ER-negative, with tucatinib for ER-positive with palbociclib. We also have early data that suggests that both approaches may reduce the development of brain metastases, an issue in HER2-positive disease, and delay time to progression of brain metastases as seen in HER2CLIMB-05 in very early data - small numbers, but still quite intriguing that you might delay progression of brain metastases with tucatinib that clearly has efficacy in the brain. So, I think that this is a hugely exciting advance for our patients, and these approaches are quickly moving into the early stage setting. T-DXd compared to standard chemo, essentially followed by THP, so a sequenced approach resulted in more pathologic complete responses than a standard THP-AC-type neoadjuvant therapy. T-DXd alone for eight cycles wasn't better, and that's interesting. We still need the sequenced non-cross-resistant chemo. But I think even more importantly, the data from DESTINY-Breast05 looking at T-DXd versus T-DM1 in patients with residual disease after neoadjuvant HER2-targeted therapy showed a remarkable improvement in invasive disease-free survival with T-DXd versus T-DM1, and quite early. It was a high-risk population, higher risk than the T-DM1 trial with KATHERINE, but earlier readout with a remarkable improvement in outcome. We expect to be FDA approved sometime in the first half of 2026. So then we'll get patients who've already had T-DXd who get metastatic disease. But my hope is that with T-DXd, maybe with tucatinib in the right group of patients or even sequenced in very high-risk disease, that we could cure many more patients with early-stage HER2-positive breast cancer and cure a subset, a greater subset of patients with de novo metastatic disease. Dr. Monty Pal: That's brilliant. And you tackled so many questions that I was going to follow up with there: brain metastases, etc. That was sort of looming in my mind. I mean, general thoughts on an ADC versus a TKI in the context of brain mets? Dr. Hope Rugo: Yeah, it's an interesting question because T-DXd has shown quite good efficacy in this setting. And tucatinib, of course, had a trial where they took patients with new brain mets, so a larger population than we've seen yet for the T-DXd trials, and saw that not only did they delay progression of brain metastases and result in shrinkage of existing untreated brain mets, but that patients who develop a new brain met, they could stay on the same assigned treatment. They got stereotactic radiation, and then the patients who were on tucatinib with trastuzumab and capecitabine had a further delay in progression of brain mets compared to those on the placebo arm, even after treatment of a new one that developed on treatment. So, I think it's hard. I think most of us for a lot of brain mets might start with the tucatinib approach, but T-DXd is also a very important treatment. You know, you're kind of trading off a diarrhea, some liver enzyme elevations with tucatinib versus nausea, which you really have to work on managing because it can be long-delayed nausea, and this risk of ILD, interstitial lung disease, that's about 12%, with most but not all trials showing a mortality rate from interstitial lung disease of just under 1 percent. In the early-stage setting, it was really interesting to see that with T-DXd getting four cycles in the neoadjuvant setting, a lot less ILD noted than the patients who got up to 14 cycles, as I think they got a median of 10 cycles in the post-surgical setting, there was a little bit more ILD. But I think we're going to be better and better at finding this earlier and preventing mortality by just stopping drug and treating earlier with steroids. Dr. Monty Pal: And this ILD issue, it always seems to resurface. There are drugs that I use in my kidney cancer clinic, everolimus, common to perhaps the breast cancer clinic as well, pembrolizumab, where I think the pattern of pneumonitis is quite different, right? What is your strategy for recognizing pneumonitis early in this context? Dr. Hope Rugo: Well, it is, and you know, having done the very early studies in everolimus where we gave it in the neoadjuvant setting and we're like, "Hmm, the patient came in with a cough. What's going on?" You know, we didn't know. And you have mouth sores, you know, we were learning about the drug as we were giving it. What we don't do with everolimus and CDK4/6 inhibitors, for example, is grade 1 changes like radiation pneumonitis, we don't stop, we don't treat it. We only treat for symptoms. But because of the mortality associated with T-DXd, albeit small, we stop drug for grade 1 imaging-only asymptomatic pneumonitis, and some of us treat with a half dose of steroids just to try and hasten recovery. We've actually now published or presented a couple of datasets from trials, a pooled analysis and a real-world analysis, that have looked at patients who were retreated after grade 1 pneumonitis or ILD and tolerated drug very well and none of them died of interstitial lung disease, which was really great to see because you can retreat safely and some of these patients stayed on for almost a year benefiting from treatment. So, there's a differential toxicity profile with these drugs and there are risk factors which clearly have identified those at higher risk: prior ILD, for example. A French group said smoking; other people haven't found that, maybe because they smoked more in France, I don't know. And being of Japanese descent is quite interesting. The studies just captured that you were treated in Japan, but I think it's probably being of Japanese descent with many drugs that increases your risk of ILD. And, you know, older patients, people who have hypoxia, those are the patients. So, how do we do this? With everolimus, we don't have specific monitoring. But for T-DXd we do; we do every nine weeks to start with and then every 12 weeks CT scans because most of the events occur relatively early. Somebody who's older and at higher risk now get the first CT at six weeks. Dr. Monty Pal: This is super helpful. And I have to tell you, a lot of these drugs are permeating the bladder cancer space which, you know, is ultimately going to be a component of my practice, so thank you for all this. We could probably stay on this topic of HER2-positive disease forever. I'm super interested in that space still. But let me shift gears a little bit and talk about triple-negative breast cancer and this evolving space of HR-positive, HER2-low breast cancer. I mean, tell us about ADCs in that very sort of other broad area. Dr. Hope Rugo: So triple-negative disease is the absolute hardest subset of disease that we have to treat because if you don't have a great response in the early stage setting, the median survival is very short, you know, under two years for the majority of TNBCs, with the exception of the small percentage of low proliferative disease subsets. The co-question is what do we do for these patients and how do we improve outcome? And sacituzumab govitecan has been one strategy in the later line setting that was shown to improve progression-free and overall survival, the Trop-2 ADC. We had recently three trials presented with the two ADCs, sacituzumab govitecan and the other Trop-2 ADC that's approved for HR-positive disease, datopotamab deruxtecan. And they were studied in the first-line setting. Two trials with SG, sacituzumab govitecan, those trials, one was PD-L1 positive, ASCENT-04. That showed that SG with a checkpoint inhibitor was superior, so pembrolizumab was superior to the standard KEYNOTE-355 type of treatment with either a taxane or gemcitabine and carboplatin with pembrolizumab for patients who have a combined positive score for PD-L1, 10 or greater. So, these are patients who are eligible for a checkpoint inhibitor, and SG resulted in an improved progression-free survival. The interesting thing about that dataset is that few patients had received adjuvant or neoadjuvant checkpoint inhibitor, which is fascinating because we give it to everybody now. But access is an issue and timing of the study enrollment was an issue. The other thing which I think we've all really applauded Gilead for is that there was automatic crossover. So, you could get from the company, to try and overcome some of the enormous disparities worldwide in access to these life-saving drugs, you could get SG through the company for free once you had blinded independent central review confirmation of disease progression. Now, a lot of the people who got the SG got it through their insurance, they didn't bill the company, but 80 percent of patients in the control arm received SG in the second-line setting. So that impacts your ability to look at overall survival, but it's an incredibly important component of these trials. So then at ESMO, we saw the data from SG and Dato-DXd in the first-line metastatic setting for patients who either had PD-L1-negative disease or weren't eligible for an immunotherapy. For the Dato study, TROPION-Breast02, that was 10 percent of the patients who had PD-L1-positive disease but didn't get a checkpoint inhibitor, and for the ASCENT-03 trial population it was only 1 percent. Importantly, the trials allowed patients who relapsed within a year of receiving their treatment with curative intent, and the Dato study, TB-02, allowed patients who relapsed while on treatment or within the first six months, and that was 15 percent of the 20 percent of early relapsers. The ASCENT trial, ASCENT-03, had 20 percent who relapsed between 6 and 12 months. The drugs were better than standard of care chemotherapy, the ADCs in both trials, which is very nice. Different toxicity profiles, different dosing intervals, but better than standard of care chemotherapy in the disease that's hardest for us to treat. And importantly, when you looked at the subset of early relapsers, those patients also did better with the ADC versus chemotherapy, which is incredibly important. And we were really interested in that 15 percent of patients who had early relapse. I actually think that six months thing was totally contrived, invented, you know, categorization and doesn't make any sense, and we should drop it. But the early relapsers were 15 percent of TB-02 and Dato was superior to standard of care chemo. We like survival, but the ASCENT trial again allowed the crossover to an approved ADC that improved survival and 80 percent of patients crossed over. In the Dato trial, they did not allow crossover, they didn't provide Dato, which isn't approved for TNBC but is for HR-positive disease, and they didn't allow, of course, pay for SG. So very few patients actually crossed over in their post-treatment data and in that study, they were able to show a survival benefit. So actually, I think in the U.S. where we can use approved drugs already before there's a fixed FDA approval, that people are already switching to use SG or Dato in the first-line setting for metastatic TNBC that's both PD-L1 positive for SG and PD-L1 negative for both drugs. And I think understanding the toxicity profiles of the two drugs is really important as well as the dosing interval to try and figure out which drug to use. Dr. Monty Pal: Brilliant. Brilliant. Well, I'm going to shift gears a little bit. ADCs are a topic, again, just like HER2-positive disease we could stay on forever. Dr. Hope Rugo: Huge. Yes. Dr. Monty Pal: But we're going to shift gears to another massive topic, which is oral SERDs. In broad strokes, right, this utilization of CDK4/6 inhibitors in the context of HR-positive breast cancer is obviously, you know, a paradigm that's been well established at this point. Where do we sequence in oral SERDs? Where do they fit into this paradigm? Dr. Hope Rugo: Ha! This is a rapidly changing area; we keep changing what we're saying every other minute. And I think that there are three areas of great interest. So one is patients who develop ESR1 mutations that allow constitutive signaling through the estrogen receptor, even when there's not estrogen around, and that is a really important mutation that is subclonal; it develops under the pressure of treatment in about 40 percent of patients. And it doesn't happen when you first walk in the door. And what we've seen is that oral SERDs as single agents are better than standard single-agent endocrine therapy in that setting. The problem that we've had with that approach is that we're now really interested in giving targeted agents with our endocrine therapies, not just in the first-line setting where CDK4/6 inhibitors are our standard of care with survival benefit for ribociclib and, you know, survival benefit in subsets with other CDK4/6 inhibitors, and abemaciclib with a numeric improvement. So we give it first line. The question is, what do you do in the second-line setting? Because of the recent data, we now believe that oral SERDs should be really given with a targeted agent. And some datasets which were recently presented, which I think have helped us with that, have been EMBER-3 and then the most recently evERA BC, or evERA Breast Cancer, that looked at the oral SERD giredestrant with everolimus compared to standard of care endocrine therapy with everolimus, where 100 percent of patients received prior CDK4/6 inhibitor and showed a marked improvement in progression-free survival, including in the subsets of patients with a short response, 6-12 months of prior response to CDK4/6 inhibitor and in those who had a PIK3CA pathway mutation. The thing is that the benefit looks like it's much bigger in the ESR1 mutant population, although response was better, PFS wasn't better in the wild type. So, we're still trying to figure that out. We also saw EMBER-3 with imlunestrant and abemaciclib as a second line. Not everybody had had a prior CDK4/6 inhibitor; they compared it to imlunestrant alone, but still the data was quite striking and seemed to cross the need for ESR1 mutations. And then lastly, we saw data from the single arms of the ELEVATE trial looking at elacestrant with everolimus and abemaciclib and showed these really marked progression-free survival data, even though single-arm, that crossed the mutation status. At least for the everolimus combination, abemaciclib analysis is still to come in the mutated subgroups. But really remarkable PFS, much longer. Single-agent fulvestrant after CDK4/6 inhibitor AI has a PFS in like the three-month range and in some studies, maybe close to five months. These are all at 10-plus months and really looking very good. And so those questions are, is it ESR1 mutation alone? Is it all comers? We'd like all comers, right? We believe in the combination approach and we're learning more about combinations with drugs like capivasertib and other drugs as we move forward. Everybody now wants to combine their targeted agent with an oral SERD because they're clearly here to stay with quite remarkable data. The other issue, so the second issue in the metastatic setting is, does it make a difference if we change to an oral SERD before radiographic imaging evidence of progression? And that was the question asked in the SERENA-6 trial where patients had serial monitoring for the presence of ESR1 mutations in ctDNA. And those who had them without progression on imaging could be randomized to switch to camizestrant with the same CDK4/6 inhibitor or stay on their same AI CDK4/6 inhibitor. And they showed a difference in progression-free survival that markedly favored camizestrant. But interestingly, the people who were on the standard control arm had an ESR1 mutation, we think AIs don't work, they stayed on for nine more months. The patients who were on the camizestrant stayed on for more than 16 months. And they presented some additional subset data which showed the same thing: follow-up PFS data, PFS2, all beneficial in SERENA-6 at the San Antonio [Breast Cancer Symposium]. So, we're still a little bit unclear about that. They did quality of life, and pain was markedly improved. They had a marked delayed time to progression of pain in the camizestrant arm. So this is all a work in progress, trying to understand who should we switch without progression to an oral SERD based on this development of this mutation that correlates with resistance. And, you know, it's interesting because the median time to having a mutation was 18 months and the median time to switch was almost 24 months. And then there were like more than 3,000 patients who hadn't gotten a mutation, hadn't switched, and were still okay. So screening everybody is the big question, and when you would start and who you would change on and how this affects outcome. Patients didn't have access to camizestrant in the control arm, something we can't fix but we have experimental drugs. We're actually planning a trial, I hope in collaboration with the French group Unicancer, and looking at this exact question. You know, if you switch and you change the CDK4/6 inhibitor and then you also allow crossover, what will we see? Dr. Monty Pal: We're coming right to the tail end of our time here, and I could probably go on for another couple of hours with you here. But if you could just give us maybe one or two big highlights from San Antonio, any thoughts to leave our audience with here based on this recent meeting? Dr. Hope Rugo: Yeah, I mean, I talked about a lot of those new data already from San Antonio, and the one that I'd really like to mention which I think was, you know, there were a lot of great presentations including personalized screening presented from the WISDOM trial by my colleague Laura Esserman, fascinating and really a big advance. But lidERA was the big highlight, I think, outside of the HER2CLIMB-05 which I talked about earlier in HER2-positive disease. And this study looked at giredestrant, the oral SERD versus standard of care endocrine therapy as treatment for medium and high-risk early-stage breast cancer. And what they showed, which I think was really remarkable with just about a three-year median follow-up, was an improvement in invasive disease-free survival with a hazard ratio of 0.7. I mean, really quite remarkable and so early. It looked as though this was all driven by the high-risk group, which makes sense, not the medium risk, it's too early. And also that there was a bigger benefit in patients who were on tamoxifen compared to giredestrant versus AI, but for both groups, the confidence intervals didn't cross 1. There's even a trend towards overall survival, even though it's way too early. I think that, you know, really well-tolerated oral drug that could improve outcome in early-stage disease, this is the first advance we've seen in over two decades in the treatment of early-stage hormone receptor-positive disease with just endocrine therapy. I think we think that we don't want to give up CDK4/6 inhibitors because we saw a survival benefit with abemaciclib and a trend with giving ribociclib in the NATALEE trial. So we're thinking that maybe one approach would be to give CDK4/6 inhibitors and then switch to an oral SERD or to have enough data to be able to give oral SERDs with these CDK4/6 inhibitors for early-stage disease. And that's all in the works, you know, lots of studies going on. We're going to see a lot of data with both switching 8,000 patients with an imlunestrant switching trial, an elacestrant trial going on, and safety data with giredestrant with abemaciclib and soon to come ribociclib. So, this is going to change everything for the treatment of early-stage breast cancer, and I hope cure more patients of the most common subset of the most common cancer diagnosed in women worldwide. Dr. Monty Pal: Super exciting. It's just remarkable to hear how this has evolved since 25 years ago, which is really the last time I sort of dabbled in breast cancer. Thank you so much, Hope, for joining us today. These were fantastic insights. Appreciate you being on the ASCO Daily News Podcast and really want to thank you personally for your remarkable contribution to the field of breast cancer. Dr. Hope Rugo: Thank you very much, and thanks for talking with me today. Dr. Monty Pal: You got it. And thanks a lot to our listeners today as well. You'll find links to all the studies we discussed today in the transcript of this episode. Finally, if you value the insights that you hear today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinion of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers: Dr. Monty Pal @montypal Dr. Hope Rugo @hoperugo Follow ASCO on social media: ASCO on X ASCO on Bluesky ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Monty Pal: Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis Dr. Hope Rugo: Honoraria: Mylan/Viatris, Chugai Pharma Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx
#189 - Your Mouth Might Be Aging You: The Shocking Oral-Body Health Connection with Dr. Sanda Moldovan from Beverly Hills Health & Dental Wellness Mercury, Root Canals, Mold, Fluoride, Fillings, and Fatigue with Dr. Sanda Moldovan What if your gums, teeth, and tongue were quietly dictating everything from your hormones to your brain health? In this mind-bending episode, Lisa sits down with Dr. Sanda Moldovan, double-board-certified periodontist, nutritionist, and founder of Beverly Hills Health & Dental Wellness, to explore how your oral microbiome shapes your entire body. We're talking mercury toxicity, root canal infections, fluoride myths, and the bacteria in your mouth linked to Parkinson's, Alzheimer's, and even autoimmune disease. Dr. Sanda explains what biological dentistry really is, why it's the future of oral health, and how to start detoxing your mouth for better energy, longevity, and brain clarity. You'll learn:
Shawn & Janet Needham R.Ph. have Dr. Nicole Lovat on the podcast to discuss if oral estradiol causes clots. Dr. Nicole Lovat Website | https://fireflymedical.net Instagram | https://www.instagram.com/fireflymedical Facebook | https://www.facebook.com/fireflymedical X | http://www.x.com/fireflymed Health Solutions Instagram | https://www.instagram.com/health_solutions_shawn_needham/ TikTok | https://www.tiktok.xcom/@healthsolutionspodcast Facebook | https://www.facebook.com/HealthSolutionsPodcast Moses Lake Professional Pharmacy Website | http://mlrx.com.com/ Facebook | https://www.facebook.com/MosesLakeProfessionalPharmacy/ Shawn Needham X| https://x.com/ShawnNeedham2 Shawn's Book | http://mybook.to/Sickened_The_Book Additional Links https://linktr.ee/mlrx
Lawrence Blatt, Chairman, President, and CEO of Aligos Therapeutics, describes the current gaps in treating the hepatitis B virus and how the disease can potentially lead to end-stage liver disease and liver cancer. Current therapies were initially developed for HIV and can suppress the virus but not eliminate or prevent the disease. The lead Aligos drug candidate blocks all steps of viral replication and prevents the virus from integrating into infected liver cells, where it can activate cancer-causing genes. Lawrence explains, "Hepatitis B virus is actually the most prevalent chronic viral infection in the world that makes patients very ill, and they can actually die from this disease. There's almost 250 million, a little bit more than 250 million people infected with Hepatitis B. And it really affects people in all walks of life across many different demographic groups. So there's not a typical HPV patient out there." "So HBV needs to be treated for life, currently very similar to HIV, and actually HBV and HIV share common features. And early on in the HIV epidemic, patients who were treated with a class of drug called nucleoside analogs, who were also coinfected with HBV, we saw responses to those drugs. So the drugs that worked in HIV, called nucleoside or nucleotide analogs that were purposely built for HIV, worked against HBV, and they worked to a certain degree. They can suppress the virus, but they can't eliminate the virus, and they can't completely suppress all the components of the viral lifecycle that end up causing disease." "So we're not going to affect the damage that's there initially, but we're blocking that damage from occurring. Now, one thing that's really interesting is that our livers are regenerative organs. So the liver is constantly replacing itself with new healthy hepatocytes or cells that make up the liver. And so if you could block the ongoing disease processes, the liver will have time to heal itself and eventually reverse the scarring. And that's really the only organ in our body that can regenerate. If you get scarring on your lungs or any other part of your body, that is for life. But in the liver, if you block the disease processes, you can reverse that scarring. So it's a very important and unique finding." #AligosTherapeutics #HepatitisB #Biotechnology #DrugDevelopment #LiverHealth #ClinicalTrials #MedicalBreakthrough #PatientCare #Virology #PharmaceuticalInnovation #Vaccines Aligos.com Listen to the podcast here
Lawrence Blatt, Chairman, President, and CEO of Aligos Therapeutics, describes the current gaps in treating the hepatitis B virus and how the disease can potentially lead to end-stage liver disease and liver cancer. Current therapies were initially developed for HIV and can suppress the virus but not eliminate or prevent the disease. The lead Aligos drug candidate blocks all steps of viral replication and prevents the virus from integrating into infected liver cells, where it can activate cancer-causing genes. Lawrence explains, "Hepatitis B virus is actually the most prevalent chronic viral infection in the world that makes patients very ill, and they can actually die from this disease. There's almost 250 million, a little bit more than 250 million people infected with Hepatitis B. And it really affects people in all walks of life across many different demographic groups. So there's not a typical HPV patient out there." "So HBV needs to be treated for life, currently very similar to HIV, and actually HBV and HIV share common features. And early on in the HIV epidemic, patients who were treated with a class of drug called nucleoside analogs, who were also coinfected with HBV, we saw responses to those drugs. So the drugs that worked in HIV, called nucleoside or nucleotide analogs that were purposely built for HIV, worked against HBV, and they worked to a certain degree. They can suppress the virus, but they can't eliminate the virus, and they can't completely suppress all the components of the viral lifecycle that end up causing disease." "So we're not going to affect the damage that's there initially, but we're blocking that damage from occurring. Now, one thing that's really interesting is that our livers are regenerative organs. So the liver is constantly replacing itself with new healthy hepatocytes or cells that make up the liver. And so if you could block the ongoing disease processes, the liver will have time to heal itself and eventually reverse the scarring. And that's really the only organ in our body that can regenerate. If you get scarring on your lungs or any other part of your body, that is for life. But in the liver, if you block the disease processes, you can reverse that scarring. So it's a very important and unique finding." #AligosTherapeutics #HepatitisB #Biotechnology #DrugDevelopment #LiverHealth #ClinicalTrials #MedicalBreakthrough #PatientCare #Virology #PharmaceuticalInnovation #Vaccines Aligos.com Download the transcript here
Plus: Meta delays roll out of smartglasses to countries outside the U.S. amid high American demand. And a Bill Gates-backed nuclear fusion company has teamed up with Nvidia and Siemens. Julie Chang hosts. Learn more about your ad choices. Visit megaphone.fm/adchoices
Fertility Docs Uncensored is hosted by Dr. Carrie Bedient from the Fertility Center of Las Vegas, Dr. Susan Hudson from Texas Fertility Center, and Dr. Abby Eblen from Nashville Fertility Center. This episode answers key patient questions about polycystic ovary syndrome (PCOS) and fertility. We answer:· How is PCOS diagnosed? Using the Rotterdam criteria: irregular cycles, more than 12 microfollicles per ovary, or elevated male hormones. Two of three confirm the diagnosis.· Does stopping birth control pills help fertility? No. PCOS cycles return to baseline because the hormonal system does not reset.· Why don't patients with PCOS ovulate regularly? The brain does not release enough FSH to trigger ovulation.· What fertility treatments work? Oral ovulation-induction medications succeed in about 80% of patients.· Do patients with PCOS have ovarian cysts? No. Small follicles are normal; true cysts are a different condition.· Does weight affect PCOS? Yes. Weight gain or loss can influence hormone balance and ovulation.We also clarify why the name “polycystic ovary syndrome” is misleading. Patients with PCOS do not have true ovarian cysts. Instead, they have many small follicles, each containing an immature egg, which are a normal part of ovarian anatomy. True ovarian cysts, such as desmoids or endometriomas, represent entirely different medical conditions and are not part of PCOS. This episode provides clear, evidence-based guidance on PCOS diagnosis, myths, and effective fertility treatment.
Send us a textSummary: I separate cold-season fact from folklore so you know what truly prevents colds, what (slightly) shortens them, what eases symptoms—and what to skip. Save money, feel better, and keep it simple.What we coverHow common colds are and how long they last (2–3 per year on average; usually 5–7 days; cough can linger).Prevention audit: Vitamin C doesn't prevent colds in the general population (Cochrane), though it helped in physically stressed groups; handwashing probably helps (Cochrane) echinacea doesn't pan out (Cochrane) garlic didn't reduce colds but modestly reduced severity in one RCT (trial) gargling showed a very small signal (trial)Grandma's wisdom check: Short sleep (
Top 5 Topics:- 2 Years Of High Unmatched 6-Year OMFS Program Numbers, & the Future of Oral Surgery Training- Periodontists vs Oral Surgeons: The Silent Battle for Implants, Sedation & Dental School Influence- Is Office Anesthesia in Danger? The Fight to Save OMFS Sedation from CRNAs, Hospital Politics, And Misleading Data- The Economics of Becoming an Oral Surgeon: $750,000 Debt, Low Reimbursement & the New Reality- How Oral Surgery Can Survive: Marketing, Value, Full-Arch Implants, and Reclaiming the Specialty In The Dental SchoolQuotes & Wisdom:04:07 – “Oral surgery is the great bridge between dentistry and medicine.”05:37–06:56 – “You have to know when to step back… I think 25 years is a good run. I'll always be motivated to teach and motivated to share knowledge. That's been my passion from the beginning.”09:49–10:31 – “Along the way I grabbed my MBA as well… taking night school for three years every Monday night for four hours… Now, having the MBA has allowed me to kind of see the errors that I made early on in my own practice.”14:55–15:26 – “Our students are the consumer of the programs… If you look at the dynamics and the history of the specialty and what the specialty wanted to do 30 years ago, it may not be what the product of the specialty wants to do now.”18:56–19:44 – “You have to market. You've got to market to the consumer what the value is. And if that perceived value makes sense to the person, then you've got a win-win.”29:21–30:40 – “You think back to your own personal experience with the specialty… There is that one experience that really hits you in the heart, and you hold onto that experience and that's why you chose this field… You have to derive the value of the specialty for you, and it's going to be different for every individual.”38:17–39:06 – “I love this specialty. You want it to flourish. I want it to be there many years beyond my own existence, and that we're at the cutting edge… We want to expand without losing anything.”55:14–55:41 – “I think the data is going to be our defense… How many fewer patients would actually receive care if they didn't have access to our ability to give them anesthesia in dentistry? How can you argue with numbers?”Questions:05:23 - “Why this step back? To private practice at this point and step away from the director role?”13:23 – “Don't think all those years and rotations are necessary—how many rectal exams do you really need to do as an oral surgery resident, you know what I mean?”17:38 - “I get this question all the time: why the 6-year versus the 4-year OMS program? What did the 6-year track benefit for you, and what do you recommend for others to pursue with the MD?”21:11 – “If periodontists are filling the gap at the dental schools—doing implants, sedations, managing complications—what does that mean for oral surgery's foothold and for who gets called when something goes wrong?”32:32 – “If we don't make full-arch ‘all-on-X' a real requirement in OMFS training, is one of the other professions going to step in and own that space instead of us?”41:13 – “What drove you, during residency at Case Western, to go into the cosmetics direction? Did any other people from your program graduate and take that same path?”43:59 – “Do you have any residents rotate through your practice right now, or is it very separate from the residency?”
This podcast was created using NotebookLM. This podcast highlights the critical link between Type 2 diabetes and various oral fungal pathologies, noting that mouth issues often serve as early indicators of systemic disease.
What if case acceptance didn't feel like "selling" at all? In this first episode of 2026, Dr. Len Tau sits down with Dr. Camesia Matthews to explore a powerful new way to help patients truly understand—and say yes to—their treatment plans. Dr. Matthews introduces her Dental Fitness Method, a five-pillar framework that connects oral health to whole-body wellness. By reframing dentistry through prevention, posture, protection, presentation, and psychology, she shows how dentists can increase patient buy-in, reduce resistance, and empower patients to take ownership of their health—without feeling pushy or sales-driven. This conversation is a must-listen for any dentist looking to improve case acceptance through clarity, education, and trust. What You'll Learn Why patients reject treatment when they don't understand the why behind it How the Dental Fitness Method reframes dentistry as whole-body healthcare The five pillars that help patients make sense of complex treatment plans How education eliminates objections and builds long-term trust Why mindset and psychology are the foundation of case acceptance How wellness-based communication leads to more confident, informed "yes" decisions — Key Takeaways 00:43 Episode Introduction & Welcome to 2026 02:48 Meet Dr. Camesia Matthews 04:30 Education, Frameworks, and Patient Buy-In 05:35 The Five Pillars of the Dental Fitness Method 08:17 Why Patients Need a Unified Oral-Health Message 10:28 What Happens When Patients Don't Understand the "Why" 12:45 Sports Dentistry, Inflammation, and Whole-Body Health 14:58 Real Case Example: Transforming Confidence Through Dental Fitness 18:40 The Future of Dentistry as Healthcare 20:32 Removing the Pressure of "Selling" Dentistry 24:10 Handling the Informed "No" 26:44 Following Up Without Losing Patients 28:46 The Dental Fitness Advantage Book 29:40 Lightning Round Q&A 35:15 How to Connect with Dr. Camesia Matthews — Connect with Dr. Camesia Instagram: @drcamesiaamatthews Book: The Dental Fitness Advantage (available on Amazon & Shopify) Learn more & connect: DentalFitnessPillars.com/educate — Learn proven dental marketing strategies and online reputation management techniques at DrLenTau.com. This podcast is sponsored by Dental Intelligence. Learn more here. This podcast is sponsored by CallRail, call tracking & lead conversion software for dentists. Find out more here. Raving Patients Podcast is your go-to place for the latest and best dental marketing strategies that will help you skyrocket your practice. Follow us for more!
Today, we're diving into an exciting development in obesity treatment—oral semaglutide. Last week, the FDA approved Novo Nordisk's Wegovy pill as the first and only oral GLP-1 for weight loss in adults. This approval is based on results from the OASIS-4 phase 3 clinical trial showing that a once-daily oral version of semaglutide can deliver nearly the same weight loss results as the injectable form. So, what does that really mean for patients and treatment options? Let's break it down. Read the Full Episode Transcript: https://pepties.com/oral-semaglutide/ Dr. Nikki's Qualifications: https://bifat.life/about/ Related Links/Products Mentioned: Peptide Podcast Partners Page https://pepties.com/partners/ BioLongevity Labs (Purchase Peptides online) Use our link and enter COUPON CODE: PEPTIDEPODCAST at checkout to receive 15% off your total order https://go.biolongevitylabs.com/aff_c?offer_id=1&aff_id=1582&aff_sub=PEPTIDEPODCAST Momentous Supplements (we use Creatine, Vital Aminos, Whey Protein) https://crrnt.app/MOME/OqGQOxGA LMNT – More Salt, Not Less. https://elementallabs.refr.cc/default/u/johnjavit Thorne Supplements (we use Omega-3 with CoQ10, Red Yeast Rice, Zinc) https://get.aspr.app/SH1KvW Organifi Creatine and Shilajit Gummies http://rwrd.io/rlbkajm?c MitoZen (methylene blue for Cognitive Function, Anti-Aging, Mental Clarity) https://www.mitozen.com/ref/cnlwiztypt/ For skin and hair health (Copper Tripeptide-1) Visit Luminose by Entera for an exclusive offer for Peptide Podcast listeners! ** Promo code PEPTIDEPODCAST at checkout for 10% off an order or 10% off the first month of a subscribe-and-save. ** https://www.enteraskincare.com/?rfsn=8906839.f93c72 NAD+ Push Patch: https://www.pushpatch.com/
Get Ready for a Sex Education Like No Other: We're Talking Fantasies, Oral Sex, and Everything in Between Whether you're partnered or solo, this episode is full of actionable insights that can help you connect more deeply, communicate more clearly, and bring more pleasure into your life and relationships. Dr. Aly also shares details about her upcoming courses, retreats and intimacy coaching. Sexual and Emotional Intimacy Skills online course on Weds, Jan 27th-Mar 17th We all receive messages about who we are supposed to be, how we ought to feel, and how we should express ourselves, often enforced through shame and disconnection. Featuring 8 classes with a woven balance of science-based data, embodied exploration, and skills development designed to support you in creating, deepening, and sustaining sexual and emotional intimacy in your relationship(s). Recordings available for those who can't attend live or want extra review. Use code "shameless" for $100 off! Sustainable Intimacy: Refuel Passion for Lasting Love retreat for couples in April 23rd-26th in Sonoma, CA (also available as an on-demand course rental) Differences in desire, changing needs, and the pressures of daily life can crowd out time for intimacy. Whether your goal is to rekindle passion or simply carve out meaningful time together, this 3-night, 4-day retreat offers a supportive space to slow down and savor each other. Uncover what's blocking intimacy and gain customized tools to support your unique dynamic. Plus, indulge in delicious meals, a heated pool and hot tub, scenic trails, movement and mindfulness classes, a workshop on passionate and dominant touch, and a sensual soirée. Early Bird tickets currently on sale for $200 off! And reach out to Dr. Aly for 1:1 and couples coaching! To learn more go to www.TurnON.love https://www.turnon.love/sexual-and-emotional-intimacy-skillshttps://www.turnon.love/sustainable-intimacy-retreat https://www.turnon.love/sex-and-intimacy-coaching For full episodes: #253 Keeping it Hot with Fantasies and Role Play #405 How to Eat Pu$$y Like a Champ 2.0 #425 How to Suck That D Like a Champ Learn more about the Intimacy Rewired program on episode #458 or click here: https://www.intimacyrewired.com. And mention Shameless Sex to get $100 off! Do you love us? Do you REALLY love us? Then order our book now! Go to shamelesssex.com to snag your copy Support Shameless Sex by sending us gifts via our Amazon Wish List Other links: Get Erika Lust's beautiful , connected, ethical, and SUPER HOT porn at http://erikalust.com, and use code XMAS45 to get 45% off! Get 10% off + free shipping with code SHAMELESS on Uberlube AKA our favorite lubricant at http://uberlube.com Get 10% off while learning the art of pleasure at http://OMGyes.com/shameless Get 15% off all of your sex toys with code SHAMELESSSEX at http://purepleasureshop.com
The woman who announced Alex Murdaugh's guilty verdict is now wearing handcuffs herself. In one of the most shocking reversals in recent courtroom history, former Colleton County Clerk of Court Becky Hill has been charged with obstruction of justice, misconduct in office, and perjury—casting a dark cloud over one of America's most watched murder trials. In this explosive Hidden Killers breakdown, Tony Brueski unpacks how Hill allegedly allowed sealed trial evidence to be photographed, violated multiple court orders, and used her powerful role in the Murdaugh trial to promote her own book, Behind the Doors of Justice. Prosecutors say she lied under oath about leaking evidence. Investigators say she broke the rules she was sworn to uphold. And Murdaugh's defense says this validates everything they've been arguing for a year: the trial wasn't fair. But that's only half the story. Murdaugh's 132-page appeal to the South Carolina Supreme Court claims his double-murder trial was fundamentally compromised—citing Hill's alleged juror influence, flawed forensics, and the admission of six days of unrelated financial-crimes testimony. The defense also points to newly discovered text messages from Curtis “Eddie” Smith that were never turned over. Hill's arrest doesn't prove jury tampering — but it raises enough questions to destabilize confidence in the verdict. The State insists that while Hill's actions were inappropriate, they don't warrant a new trial. The defense says the integrity of the justice system is already shattered. Oral arguments could come this fall, but a ruling may not land until 2026. One thing is certain: Becky Hill's arrest didn't just ignite a scandal—it may have opened the door for Alex Murdaugh's last and most powerful shot at a retrial. #BeckyHill #AlexMurdaugh #MurdaughTrial #MurdaughAppeal #TrueCrimeNews #CourtroomDrama #ObstructionOfJustice #LegalScandal #HiddenKillers #TonyBrueski Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspod Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/tonybpod Listen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872
Hidden Killers With Tony Brueski | True Crime News & Commentary
The woman who announced Alex Murdaugh's guilty verdict is now wearing handcuffs herself. In one of the most shocking reversals in recent courtroom history, former Colleton County Clerk of Court Becky Hill has been charged with obstruction of justice, misconduct in office, and perjury—casting a dark cloud over one of America's most watched murder trials. In this explosive Hidden Killers breakdown, Tony Brueski unpacks how Hill allegedly allowed sealed trial evidence to be photographed, violated multiple court orders, and used her powerful role in the Murdaugh trial to promote her own book, Behind the Doors of Justice. Prosecutors say she lied under oath about leaking evidence. Investigators say she broke the rules she was sworn to uphold. And Murdaugh's defense says this validates everything they've been arguing for a year: the trial wasn't fair. But that's only half the story. Murdaugh's 132-page appeal to the South Carolina Supreme Court claims his double-murder trial was fundamentally compromised—citing Hill's alleged juror influence, flawed forensics, and the admission of six days of unrelated financial-crimes testimony. The defense also points to newly discovered text messages from Curtis “Eddie” Smith that were never turned over. Hill's arrest doesn't prove jury tampering — but it raises enough questions to destabilize confidence in the verdict. The State insists that while Hill's actions were inappropriate, they don't warrant a new trial. The defense says the integrity of the justice system is already shattered. Oral arguments could come this fall, but a ruling may not land until 2026. One thing is certain: Becky Hill's arrest didn't just ignite a scandal—it may have opened the door for Alex Murdaugh's last and most powerful shot at a retrial. #BeckyHill #AlexMurdaugh #MurdaughTrial #MurdaughAppeal #TrueCrimeNews #CourtroomDrama #ObstructionOfJustice #LegalScandal #HiddenKillers #TonyBrueski Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspod Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/tonybpod Listen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872
The woman who announced Alex Murdaugh's guilty verdict is now wearing handcuffs herself. In one of the most shocking reversals in recent courtroom history, former Colleton County Clerk of Court Becky Hill has been charged with obstruction of justice, misconduct in office, and perjury—casting a dark cloud over one of America's most watched murder trials. In this explosive Hidden Killers breakdown, Tony Brueski unpacks how Hill allegedly allowed sealed trial evidence to be photographed, violated multiple court orders, and used her powerful role in the Murdaugh trial to promote her own book, Behind the Doors of Justice. Prosecutors say she lied under oath about leaking evidence. Investigators say she broke the rules she was sworn to uphold. And Murdaugh's defense says this validates everything they've been arguing for a year: the trial wasn't fair. But that's only half the story. Murdaugh's 132-page appeal to the South Carolina Supreme Court claims his double-murder trial was fundamentally compromised—citing Hill's alleged juror influence, flawed forensics, and the admission of six days of unrelated financial-crimes testimony. The defense also points to newly discovered text messages from Curtis “Eddie” Smith that were never turned over. Hill's arrest doesn't prove jury tampering — but it raises enough questions to destabilize confidence in the verdict. The State insists that while Hill's actions were inappropriate, they don't warrant a new trial. The defense says the integrity of the justice system is already shattered. Oral arguments could come this fall, but a ruling may not land until 2026. One thing is certain: Becky Hill's arrest didn't just ignite a scandal—it may have opened the door for Alex Murdaugh's last and most powerful shot at a retrial. #BeckyHill #AlexMurdaugh #MurdaughTrial #MurdaughAppeal #TrueCrimeNews #CourtroomDrama #ObstructionOfJustice #LegalScandal #HiddenKillers #TonyBrueski Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspod Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/tonybpod Listen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872
“It takes more than hormones to fix our hormones.” - Dr. Anna CabecaWhen it comes to vaginal health, pelvic floor health, and incontinence issues, hormones play a critial role. From the type of hormones to oral formulations, injections, and topicals, there are a lot of options for hormone therapy, from the delivery vehicle to the forms of hormones used.At the same time, you can't optimize hormone health through hormone replacement only. We have to take a holistic picture, starting with the gut, lifestyle, and stress management. This approach enables the body to resuscitate, repair, and rejuvenate itself, allowing it to function at its peak. At this point, hormone therapy can offer a complementary supporting role, increasing the opportunity for optimal health and wellness.Today's guest, triple board-certified OB-GYN Dr. Anna Cabeca, has been working with women in midlife for decades, and she's an advocate for a holistic approach to hormone support, which she calls hormone replenishment.In this episode, Dr. Anna and I discuss when to start thinking about supporting your hormones, the connection between gut health and hormone balance, the need for personalized treatment appraoches, detoxification pathways, and the use of topical hormones, Dr. Cabeca's products for women in midlife, how her patients have improved their vaginal health and reversed incontinence in post-menopause, and more.Enjoy the episode, and let's innovate and integrate together!---Learn more or watch the video version of this conversation at https://integrativewomenshealthinstitute.com/getting-nerdy-about-hormones-topical-transdermal-oral-oh-my-with-dr-anna-cabeca-do/.Connect with me and access our entire platform at IntegrativeWomensHealthInstitute.com (https://integrativewomenshealthinstitute.com/).Find and follow us @integrativewomenshealth on YouTube (https://www.youtube.com/@integrativewomenshealth) and Instagram (https://www.instagram.com/integrativewomenshealth/).
Send us a message with this link, we would love to hear from you. Standard message rates may apply. Oral Wegovy is officially FDA approved — but what does that actually mean for patients? In this episode of Your Checkup, we break down the December 2025 approval of oral semaglutide 25 mg for chronic weight management, who qualifies, how it works, and how effective it really is. We review the clinical trial data behind the approval, including expected weight loss, common side effects, and long-term expectations, and explain how oral Wegovy compares to injectable GLP-1 medications. We also tackle common misconceptions, dosing and lifestyle considerations, and the very real challenges of cost and insurance coverage. If you've heard the headlines and want the facts — without hype — this episode is for you. Check out our new graphics. Thank you, Vantage Design Works. Check out our website, you can send us an email, yourcheckuppod@gmail.com. Check out our website, you can find us on Instagram, share us with a friend or a neighbor. But most importantly, stay healthy, my friends.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RN Artwork Rebrand and Avatars: Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/ Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qr Original Artwork Concept: Olivia Pawlowski
Matters Microbial #120: Bacterial Interactions among Oral Microbes December 29, 2025 For Episode 120, we welcome Dr. Batbileg Bor, Associate Professor at the ADA Forsyth Institute, to the #QualityQuorum. He joins us to discuss some of the oral community's most enigmatic members: microbes that dwell on other microbes and potentially influence our own health. Host: Mark O. Martin Guest: Batbileg Bor Subscribe: Apple Podcasts, Spotify Become a patron of Matters Microbial! Links for this episode Here is a fun video about #LuxArt that Dr. Jennifer Quinn and I made for Harvard University's Microbial Sciences Initiative in 2024. Here is a wonderful essay about Dr. Rita Colwell. Here is a link to her fascinating book about her life. A blog overview of the amazing Deinococcus radiodurans. A fine article about the "artwork" that Paenibacillus creates when it forms colonies. Here is the video that two of my #Bio350 #Micronauts made…a parody of Vanilla Ice's "Ice, Ice, Baby" but about microbiology. Here is a link to the #MattersMicrobial podcast involving the fascinating work of Dr. Jessica Mark Welch on the oral microbiome. A review article on predatory bacteria. An overview of the CPR (Candidate Phyla Radiation), both prominent and mysterious. A recent article by Dr. Bor and colleagues describing the "microbial dark matter" seemingly everwhere…even in the human mouth. An introductory profile on TM7, Saccharibacteria. A solid early review of TM7, by Dr. Bor and colleagues. Dr. Bor and colleagues' early article about TM7, discussed in today's podcast. Dr. Bor and colleagues' article describing interesting interactions between the epibiont and the basibiont, described in today's podcast. Here is a related article. An article by Dr. Bor and colleagues describing the two Type IV pili systems of Saccharibacteria. A fascinating article by Dr. Bor and colleagues describing how TM7 can modulate the responses of animals in different ways, discussed on the podcast. Dr. Bor's LinkedIn profile. Dr. Bor's faculty page at the ADA Forsyth Institute. Dr. Bor's laboratory website with fabulous images to enjoy. Intro music is by Reber Clark Send your questions and comments to mattersmicrobial@gmail.com
I never thought I'd be glued to my screen watching the Supreme Court hand President Donald Trump a rare courtroom defeat, but here we are, listeners, on the heels of Christmas 2025. Just days ago, on December 23, the Justices in Washington, D.C., issued a sharp three-page unsigned order in Trump v. Illinois, rejecting the Trump administration's emergency plea to deploy the Illinois National Guard and Texas National Guard troops to Chicago. Picture this: Back on October 4, President Trump federalized 300 Illinois National Guard members to safeguard federal property amid reports of riots—protesters hurling tear gas canisters at officers, yanking off gas masks, even targeting them with bullhorns that could cause permanent hearing loss. The administration argued it was essential under federal law, citing unrefuted declarations of violence that local police in Chicago couldn't handle alone.But a federal judge in Chicago slapped down a temporary restraining order, and the Supreme Court let it stand. Justices Samuel Alito, Clarence Thomas, and Neil Gorsuch dissented fiercely—Alito's opinion called out the lower court for ignoring the facts, questioning why grand jury no-indictments for some rioters weren't enough to discredit the violence claims. Justice Brett Kavanaugh concurred separately, but the majority sided against the administration, marking a loss in the shadow docket frenzy that's defined Trump's second term. According to the Brennan Center's tracker, since January 20, 2025, the Court has ruled on 25 such emergency applications challenging Trump actions—20 at least partially in his favor, but this one, no dice. SCOTUSblog reported it straight: the deployment stays blocked while litigation drags on.This isn't isolated. Oral arguments wrapped up just last month on November 5 in Learning Resources v. Trump, consolidated with Trump v. VOS Selections before the Supreme Court. At stake? Whether the International Emergency Economic Powers Act lets President Trump slap trade tariffs during national emergencies he declares—and if so, does it unconstitutionally hand Congress's power to the executive? Dykema's legal alert calls it the term's biggest case, pitting presidential authority against separation-of-powers limits. Whispers from the bench suggest the Justices are skeptical, probing the delegation doctrine hard.Meanwhile, Trump's legal battles echo from his first term. In New York, Judge Juan Merchan's decision in People v. Donald J. Trump keeps sentencing on ice—pushed from July 2024 past the election to November 26 at Trump's own request, now stayed pending Supreme Court immunity fallout from Trump v. United States. Federal appeals upheld a jury's E. Jean Carroll verdict against him, with no reversal in sight. And the floodgates? Education policies sparked 71 lawsuits in 2025 alone, per Education Week, with Trump losing nearly 70 percent at lower courts. Immigration clashes rage on—from Noem v. Doe revoking parole for half a million from Cuba, Haiti, Nicaragua, and Venezuela, to Alien Enemies Act deportations where the Court sometimes greenlights, sometimes blocks.It's a whirlwind, listeners—tariffs, troops, tariffs again—reminding us the courts are checking power like never before. As 2025 closes, Trump's docket tests every constitutional seam.Thank you for tuning in, and come back next week for more. This has been a Quiet Please production, and for more, check out Quiet Please Dot A I.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI
Full Show Notes: https://bengreenfieldlife.com/lneniko In today's episode with Dr. Eniko Loud, Dr. Ghazal Sophia Taghavi, and Catherine Staffeldt, esteemed practitioners in the field of bioesthetic dentistry, you'll get to explore the ins and outs of holistic oral care, from proper brushing and flossing techniques to the integration of Ayurvedic practices in dental health. You'll also discover the importance of maintaining a balanced oral microbiome, the benefits of crunchy foods for jaw development, and the lesser-known impacts of dental practices on overall health, including sleep quality and systemic conditions. Plus, we'll delve into innovative treatments like tongue scraping, myofunctional therapy, and bioesthetic dentistry's role in restoring natural mouth function, and much more (like the innovative treatments and care I've been receiving from the Whole Health Dentistry Team out in Scottsdale, Arizona!). Episode Sponsors: Our Place: Upgrade to Our Place today and say goodbye to forever chemicals in your kitchen. Go to fromourplace.com and enter my code BEN at checkout to receive 10% off sitewide. Pique: Pique Teas is where plants and science intersect to produce teas and supplements of unrivaled efficacy, purity, and convenience. Go to Piquelife.com/Ben to get 20% off for life, plus a free starter kit with a rechargeable frother and glass beaker to elevate your ritual. Apollo: Apollo is a safe and non-invasive wearable that actively improves your sleep. Head over to apolloneuro.com/bengreenfield and use code BENGREENFIELD for $90 off. ZBiotics Pre-Alcohol Probiotic: The world's first genetically engineered probiotic that helps break down the toxic byproduct of alcohol, Zbiotics Pre-Alcohol allows you to enjoy your night out and feel great the next day. Order with the confidence of a 100% money-back guarantee and 15% off your first order at zbiotics.com/BEN15. BON CHARGE: BON CHARGE is a holistic wellness brand with a wide range of products that naturally address the issues of modern life. Their products can help you sleep better, perform better, recover faster, balance hormones, reduce inflammation, and so much more. Go to boncharge.com/GREENFIELD and use coupon code GREENFIELD to save 15%.See omnystudio.com/listener for privacy information.
The FDA approving the first GLP-1 pill for obesity from Wegovy maker Novo Nordisk. CNBC speaking with the CEO about expanding access and how the pill will increase the company's competitive edge. Then, former U.K. Treasury Minister Jim O'Neill. His outlook for global markets. And President Trump saying “aggressive housing reform” is coming next year. UBS helps look at possible policy changes and the impact to stocks in the sector. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this episode, Hallie Bulkin speaks with Dr. Alyssa Welch about the vital role of interprofessional collaboration in achieving optimal patient outcomes, particularly for speech-language pathologists (SLPs). Dr. Welch emphasizes that working alongside occupational therapists (OTs), physical therapists (PTs), dentists, and other specialists is not just beneficial—it is now a core competency in modern healthcare.Dr. Welch and Hallie discuss the necessity of recognizing the limits of your own expertise and knowing when to make a referral. Collaboration ensures a whole-person therapeutic approach and prevents the professional burnout that comes from trying to "fix everything" in isolation. They cover key areas where SLPs and other therapists must coordinate care, such as feeding mechanics, positioning for speech, and addressing core stability and motor skills.In this episode, you'll learn:✔️ ️ Interprofessional collaboration is essential for SLPs, leading to better patient outcomes and reduced medical errors.✔️ Collaboration often involves partnering with Occupational Therapists (OTs) for fine motor skills, positioning, and feeding mechanics, and Physical Therapists (PTs) for gross motor skills, body positioning, and trunk control.✔️ Collaboration shifts the focus from checking off individual treatment boxes to a patient-centered approach that meets the family's actual needs.✔️ Poor communication is responsible for an estimated 70-80% of serious medical errors; collaboration significantly reduces this risk.✔️ Recognizing the limits of your own scope and knowing when to refer is crucial for long-term career sustainability and preventing professional burnout.✔️ Clinical collaboration can take many forms, including email consultations, case conferences, co-treatment sessions, and shared documentation.RELATED EPISODES YOU MIGHT LOVEEpisode 234: The Role of Occupational Therapists in TOTs Care with Anna Dearman MBA, MOT, LOTR, CLCEp 332: The Interconnectedness of Oral and Systemic Health with Amber White RDH, HHPOTHER WAYS TO CONNECT & LEARN
Today we are thrilled to feature an episode from Judaism Unbound's family of podcasts on our flagship podcast's feed. The podcast is The Oral Talmud, hosted by our founder Dan Libenson and Benay Lappe – founder of SVARA: a Traditionally Radical Yeshiva.Join Benay Lappe and Dan Libenson in their chevrutah, their partnered study and exploration of the Talmud through the “traditionally radical” lens pioneered by Benay Lappe. Together, we explore key stories and practices from the Talmud as a how-to manual for re-imagining Judaism after the previous version “crashes.” Whether you are a beginner or a longtime learner of Talmud, this podcast offers a framework to understand the Talmud more deeply from the perspective of contemporary academic study and creative re-interpretation.----------------------Episode 0: Learning Together“I am responsible for my chevruta's learning, and my chevruta is responsible for my learning. I am invested in you.” - Benay LappeJoin study partners (chevrutas) Benay Lappe & Dan Libenson as they reflect on five years of The Oral Talmud, and celebrate its transition from a video-series to a podcast! What do lasting study partners recognize in each other? How do they decide how and what to learn together? Find out what makes a learning journey exciting, possible, and loving! For full episode shownotes, click here.
VIDEO Version https://youtube.com/live/JRRWz7OvEe8?feature=shareOpie kicks off the morning with the most disturbing Christmas gift ever: Gary Busey, looking straight out of a horror flick, proudly demonstrating goose honks like it's high art. Things spiral fast – from Ron the Waiter's wild sun-staring experiment revealing monkey-to-alien morphs and hieroglyphic code downloads, to raw debates on Eskimo intimacy, stolen packages (104 million a year?!), and whether prison needs make it “not gay.” They also break down the WOLD Vanity Fair interview from Trump's highly regarded Chief of Staff, Susie Wiles! Buckle up for unfiltered, irreverent rants 500 feet above NYC that'll leave you laughing, disturbed, and questioning reality.
In this episode of Science of Reading: The Podcast, Susan Lambert is joined by research scientist and professor Julie Van Dyke, Ph.D., who explains why syntax instruction may be the missing piece in our mission to improve comprehension outcomes for all students. Together, Julie and Susan discuss why syntax is the part of the language system that matters for comprehension, how the same systematicity and rule governance that you find in teaching phonics also exists in syntax, and how explicit syntax instruction could be the next breakthrough in evidence-based literacy education.Show notes:Register to join our Science of Comprehension Symposium.Submit your questions on comprehension!Connect with Julie Van Dyke on LinkedIn.Learn more about Julie Van Dyke's research on her website.Watch an interview about Syntax Comes First: Understanding How Syntax Is the Backbone of ComprehensionWatch Dr. Van Dyke's webinar: Finding the Missing Link in Reading Comprehension. Access recent Perspectives issues via the IDA. Listen to Season 2 of Amplify's Beyond My Years podcast.Join our community Facebook group.Connect with Susan Lambert.Quotes:"In English, syntax is word order. Syntax is the relationship between the entities in a sentence." —Julie Van Dyke, Ph.D."If you want to increase comprehension, you need to be explicit in syntax because that's the part of the language system that matters for comprehension." —Julie Van Dyke, Ph.D."Comprehension is the glue between the words. It's the process of gluing the words together, each word as you go." —Julie Van Dyke, Ph.D.Episode Timestamps:00:00 Introduction: Syntax and comprehension with Julie Van Dyke, Ph.D.06:00 Nervousness around syntax instruction11:00 Comprehension is the glue between words15:00 The difference between grammar and syntax19:00 How the brain learns language and how syntax is related to that learning24:00 Oral language is much less complicated than written language30:00 Explaining regressions33:00 The need to be explicit in syntax instruction36:00 How we develop fluency as syntax44:00 Closing thoughts: Syntax can move the needle on the nation's report card*Timestamps are approximate, rounded to nearest minute
© 2020-2026 Ivy Podcast Discovery LLC
